Notes
to the Unaudited Condensed Interim Consolidated Financial Statements
Note
1 – Organization of Business, Restatement and Going Concern:
Generex
Biotechnology Corporation (“Generex” or the “Company”), was formed in the State of Delaware on September
4, 1997 and its year-end is July 31. It is engaged primarily in the research and development of drug delivery systems and the
use of the Company’s proprietary technology for the administration of formulations of large molecule drugs to the oral (buccal)
cavity using a hand-held aerosol applicator; and through the Company’s wholly-owned subsidiary, Antigen Express, Inc. (“Antigen”),
has undertaken work on immunomedicines incorporating proprietary vaccine formulations.
On
January 18, 2017, the Company closed an Acquisition Agreement pursuant to which the Company acquired a 51% interest in Hema Diagnostic
Systems, LLC (“HDS”), a Florida limited liability company established in December 2000 to market and distribute rapid
test devices including infectious diseases. Since 2002, HDS has been developing an expanding line of rapid diagnostic tests (RDTs)
including such diseases as Human Immunodeficiency Virus (HIV) – 1/2, tuberculosis, malaria, hepatitis, syphilis, typhoid
and dengue as well as other infectious diseases. Subsequently, on December 1, 2018, the Company exercised its call option and
closed the acquisition of the remaining 49% interest in HDS to become a wholly owned subsidiary of the Company.
On
October 3, 2018, the Company entered into an Asset Purchase Agreement with Veneto Holdings, L.L.C. (“Veneto”) to purchase
certain assets of Veneto and its subsidiaries. The Agreement bifurcated the closing. On October 3, 2018 (the “First
Closing”), the Company purchased substantially all the operating assets of Veneto including (a)system of dispensing pharmacies,
(b) one central adjudicating pharmacy, (c) a wholesale pharmaceutical purchasing company, and (d) an in-network laboratory in
exchange for a secured promissory note in the principal amount of $15,000,000. On November 1, 2018 the Company consummated the
acquisition of the Second Closing Assets, consisting primarily of Veneto’s management services organization business and
two additional ancillary services. The aggregate price for the First Closing Assets and the Second Closing Assets was $30,000,000.
The Company issued a promissory note in the principal amount of $35,000,000 (the “
New Note
”) consisting of
the $30,000,000 purchase price and a $5,000,000 original issue discount, as the sole consideration payable on the Second Closing
Date. On January 15, 2019, the Company entered into an Amendment Agreement (the “
Amendment
”) with Veneto and
the equity owners of Veneto entered into restructuring payment of the Note. At the time of filing the Company is still negotiating
terms and as such, has not been finalized.
On
January 7, 2019, the Company closed two separate Acquisition Agreements pursuant to which the Company acquired a 51% interest
in both Regentys Corporation (“Regentys”) and Olaregen Therapeutix Inc. (“Olaregen”). Regentys is a regenerative
medicine company focused on developing novel treatments for patients with gastrointestinal (GI) disorders. Olaregen is a New York
based regenerative medicine company that is preparing to launch its proprietary, patented, wound conforming gel matrix, Excellagen,
an FDA 510K cleared wound healing product. The terms of the Regentys acquisition included an upfront payment of $400,000, plus
$14,600,000 to be paid according to a milestone-based schedule. The terms of the Olaregen acquisition included an upfront payment
of $400,000, plus $11,600,000 to be paid according to a milestone-based schedule.
Going
Concern
The
accompanying unaudited condensed interim consolidated financial statements have been prepared in conformity with US GAAP, which
contemplate continuation of the Company as a going concern. The Company has experienced negative cash flows from operations since
inception and has an accumulated deficit of approximately $403 million and a working capital deficiency of approximately $54 million
at January 31, 2019. The Company has funded its activities to date almost exclusively from debt and equity financings.
The
Company will continue to require substantial funds to implement its new investment acquisition plans. Management’s
plans in order to meet its operating cash flow requirements include financing activities such as private placements of its common
stock, preferred stock offerings, and issuances of debt and convertible debt instruments. Management is also actively pursuing
financial and strategic alternatives, including strategic investments and divestitures, industry collaboration activities and
strategic partners.
It
is management’s opinion that these conditions raise substantial doubt about the Company’s ability to continue as a
going concern for a period of twelve months from the balance sheet date. There are no assurances that such additional funding
will be achieved and that the Company will succeed in its future operations. The unaudited condensed interim consolidated financial
statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts
of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company’s inability
to obtain required funding in the near future or its inability to obtain funding on favorable terms will have a material adverse
effect on its operations and strategic development plan for future growth. If the Company cannot successfully raise additional
capital and implement its strategic development plan, its liquidity, financial condition and business prospects will be materially
and adversely affected, and the Company may have to cease operations.
Note
2 – Restatement of previously issued condensed interim consolidated financial statements
The
Company determined that its previously issued condensed interim consolidated financial statements as of and for the three and
six months ended January 31, 2019, as originally filed with the Securities and Exchange Commission on March 25, 2019, should no
longer be relied upon since the auditors had not completed their interim review and their comments were not incorporated into
the documents as filed primarily related the recent acquisitions of the assets and operations Veneto Holdings LLC, valuation and
purchase price allocations of the acquisition of Regentys and Olaregen and related notes and disclosures.
The
effects of these restatement adjustments on (i) the Company’s Condensed Interim Consolidated Balance Sheet as of January
31, 2019, (ii) the Company’s Condensed Interim Consolidated Statements of Operations and Comprehensive Loss for the three
and six months ended January 31, 2019, (iii) the Company’s Condensed Interim Consolidated Statement of Stockholders’
Equity/(Deficit) for the six months ended January 31, 2019 and (iv) the Company’s Condensed Consolidated Statement of Cash
Flows for the six months ended January 31, 2018 are presented below.
The
restatement adjustments are described below:
|
•
|
Our
balance sheets as of January 31, 2019 by recording an overall increase in Total Assets
and Total Liabilities, Redeemable Non-Controlling Interest, and Stockholder’s Equity
by approximately $310,000 as a result of recording approximately $4.0 million of Redeemable
Non-Controlling Interest, and reclassification of $3.0 million of Additional Paid-in
Capital and a reduction of approx. $1.8 million of Preferred Series A Stock related to
the acquisition of Regentys Corporation; and by recording approximately $750,000 of Additional
Paid-in Capital, and reclassification and reduction of approx. $1.0 million of Preferred
Series A Stock and additional reclassifications of accounts receivable and an increase
in cash of approximately $187,000 related to the recent acquisitions. Goodwill and intangible
assets had a net decrease of approx. $19,000 which included: increase of $143,000 to
account for the reduction of impairment of Grainland’s intangible assets, increase
of $400,000 related to the purchase price allocation adjustment of goodwill for the Regentys
acquisition, decrease of $250,000 related to the purchase price allocation adjustment
of goodwill for the Olaregen acquisition, decrease of approx. $6,000 to goodwill which
should have been classified as other current assets and decrease of intangible assets
of approx. $305,000 to record amortization on Veneto intangible assets.
|
|
•
|
Our
statements of operations for the three months and six months ended January 31, 2019.
As a result of the restatement, our consolidated net income for the three months and
six months ended January 31, 2018 increased by approximately $167,000, and a reclassification
and elimination of intercompany accounts and transactions resulting in a reduction of
approximately $1.4 million of Revenues and General and Administrative Expenses related
to the operations of the Veneto acquisition, and a reduction and reclassification of
an Impairment of a Long-Lived Asset by approximately $142,000 related other activities.
|
|
•
|
Our
statement of cash flows for the six months ended January 31, 2019 resulted in an increase
in cash of approximately $187,000 primarily from changes in the operations of the acquired
assets from Veneto acquisition.
|
|
•
|
Additional
notes and comments follow each following statement comparing the financial statements
and amounts previously filed with the restated financial statements and amounts.
|
Impacts
of restatement
The
effects of the restatement on the line items within the Company’s condensed interim consolidated balance sheets as of January 31,
2019 are as follows:
GENEREX
BIOTECHNOLOGY CORPORATION AND SUBSIDIARIES
|
UNAUDITED
CONDENSED INTERIM CONSOLIDATED BALANCE SHEETS
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
January
31, 2019
|
|
|
As
previously reported
|
|
Adjusted
|
|
|
|
Restated
|
ASSETS
|
Current Assets
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash
and cash equivalents
|
|
$
|
2,186,377
|
|
|
$
|
187,444
|
|
|
(a)
(b)
|
|
$
|
2,373,821
|
|
Accounts
receivable, net
|
|
|
2,466,138
|
|
|
|
(170,077
|
)
|
|
(a)
|
|
|
2,296,061
|
|
Inventory,
net
|
|
|
1,099,508
|
|
|
|
—
|
|
|
|
|
|
1,099,508
|
|
Other
current assets
|
|
|
280,271
|
|
|
|
6,168
|
|
|
(c)
|
|
|
286,439
|
|
Total
current assets
|
|
|
6,032,294
|
|
|
|
23,535
|
|
|
|
|
|
6,055,829
|
|
Property and equipment
|
|
|
645,607
|
|
|
|
—
|
|
|
|
|
|
645,607
|
|
Notes receivable -
noncurrent (Note 10)
|
|
|
1,406,051
|
|
|
|
—
|
|
|
|
|
|
1,406,051
|
|
Goodwill and intangible
assets (Note 11)
|
|
|
64,939,874
|
|
|
|
(18,713
|
)
|
|
(c)
|
|
|
64,921,161
|
|
Patents, net
|
|
|
21,987
|
|
|
|
—
|
|
|
|
|
|
21,987
|
|
Other
assets, net
|
|
|
18,821
|
|
|
|
—
|
|
|
|
|
|
18,821
|
|
TOTAL
ASSETS
|
|
$
|
73,064,634
|
|
|
$
|
4,822
|
|
|
|
|
$
|
73,069,456
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
LIABILITIES
AND STOCKHOLDERS’ DEFICIENCY
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Current Liabilities
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accounts
payable and accrued expenses
|
|
$
|
16,917,095
|
|
|
$
|
(53,104
|
)
|
|
(d)
|
|
$
|
16,863,991
|
|
Notes
payable, current (Note 10 and 12)
|
|
|
40,919,835
|
|
|
|
48,486
|
|
|
(d)
|
|
|
40,968,321
|
|
Loans
from related parties (Note 4)
|
|
|
13,200
|
|
|
|
—
|
|
|
|
|
|
13,200
|
|
Other
current liabilities
|
|
|
—
|
|
|
|
4,620
|
|
|
(d)
|
|
|
4,620
|
|
Deferred
tax liability (Note 10)
|
|
|
1,930,495
|
|
|
|
(540
|
)
|
|
(e)
|
|
|
1,929,955
|
|
Total
Current Liabilities
|
|
|
59,780,625
|
|
|
|
(538
|
)
|
|
|
|
|
59,780,087
|
|
Notes payable - noncurrent
|
|
|
149,637
|
|
|
|
(149,637
|
)
|
|
(f)
|
|
|
—
|
|
Other noncurrent liabilities
|
|
|
—
|
|
|
|
171,562
|
|
|
(g)
|
|
|
171,562
|
|
Derivative liability
- convertible notes (Note 12)
|
|
|
2,545,810
|
|
|
|
(192,671
|
)
|
|
(h)
|
|
|
2,353,139
|
|
Derivative liability
- warrants (Note 12)
|
|
|
—
|
|
|
|
192,671
|
|
|
(h)
|
|
|
192,671
|
|
Warrants
to be issued (Note 10)
|
|
|
—
|
|
|
|
—
|
|
|
|
|
|
—
|
|
Total
Liabilities
|
|
|
62,476,072
|
|
|
|
21,387
|
|
|
|
|
|
62,497,459
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Redeemable non-controlling
interest (Note 8)
|
|
|
—
|
|
|
|
4,073,898
|
|
|
(i)
|
|
|
4,073,898
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders’
Equity (Note 7)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Series H Convertible
Preferred Stock, $.001 par value; authorized 109,000 shares, 0 and 63,000 issued shares at January 31, 2019 and July 31, 2018,
respectively
|
|
|
—
|
|
|
|
—
|
|
|
|
|
|
—
|
|
Series I Convertible
Preferred Stock, $.001 par value; authorized 6,000 shares, 0 and 16,590 issued shares at January 31, 2019 and July 31, 2018,
respectively
|
|
|
—
|
|
|
|
—
|
|
|
|
|
|
—
|
|
Regentys Series A Redeemable
Convertible Preferred Stock, $0.0001 par value; authorized 2,793,192 shares, issued shares at January 31, 2019 and July 31,
2018, respectively.
|
|
|
1,815,575
|
|
|
|
(1,815,575
|
)
|
|
(j)(c)
|
|
|
—
|
|
Olaregen Series A Preferred
Stock, $0.001 par value; authorized 592,683 and 0 shares at January 31, 2019 and July 31, 2018, respectively; 592,683 and
0 issued shares at January 31, 2019 and July 31, 2018, respectively
|
|
|
1,000,000
|
|
|
|
(1,000,000
|
)
|
|
(k)(c)
|
|
|
—
|
|
Common stock, $.001
par value; authorized 750,000,000 and 750,000,000 shares at January 31, 2019 and July 31, 2018, respectively; 60,362,164 and
22,430,121 issued and outstanding at January 31, 2019 and July 31, 2018, respectively
|
|
|
60,362
|
|
|
|
—
|
|
|
|
|
|
60,362
|
|
Common
stock payable
|
|
|
201,294
|
|
|
|
—
|
|
|
|
|
|
201,294
|
|
Additional
paid-in capital
|
|
|
384,414,252
|
|
|
|
2,966,116
|
|
|
(l)(c)(j)(k)
|
|
|
387,380,368
|
|
Accumulated
deficit
|
|
|
(403,460,965
|
)
|
|
|
(167,104
|
)
|
|
(b)(c)(e)(f)(g)
|
|
|
(403,628,069
|
)
|
Accumulated
other comprehensive income
|
|
|
800,446
|
|
|
|
—
|
|
|
|
|
|
800,446
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-controlling
interest (Note 7)
|
|
|
25,757,598
|
|
|
|
(4,073,900
|
)
|
|
(i)
|
|
|
21,683,698
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
Stockholders’ Equity
|
|
|
10,588,562
|
|
|
|
(16,565
|
)
|
|
|
|
|
10,571,997
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
TOTAL
LIABILITIES, REDEEMABLE NON-CONTROLLING INTEREST AND STOCKHOLDERS’ EQUITY
|
|
$
|
73,064,634
|
|
|
$
|
4,822
|
|
|
|
|
$
|
73,069,456
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Going Concern (Note
1)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Commitments & Contingencies
(Note 5)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Subsequent Events (Note
12)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(a)
|
|
Adjustment
of $170,077 to (1) increase "Cash" and (2) decrease "Accounts receivable"
to recognize the collection of $170,077 of accounts receivables related to the Veneto
acquired assets
|
(b)
|
|
Adjustment
of $17,367 to decrease "Cash" to record the payment of interest related to
the Veneto acquired assets.
|
(c)
|
|
Adjustment
recorded to reduce the impairment of long-lived assets of $230,932 to $88,311 related
to the closing of the Grainland pharmacy, (2) increase goodwill by $400,000 related to
the purchase price allocation of the Regentys acquisition, (3) decrease goodwill by $250,000
related to the purchase price allocation of the Olaregen acquisition, (4) decrease goodwill
by $6,168 which should have been classified as other current assets, (5) decrease intangible
assets by $305,166 to recognize amortization expense on Veneto intangible assets.
|
(d)
|
|
Adjustment
to (1) reclassify $53,104 of "Accrued interest" to "Notes payable, current"
related to the acquisition of Olaregen, and (2) reclassify $4,620 from "Notes payable"
to "Other current liability".
|
(e)
|
|
Adjustment
of $540 of "Deferred tax liability" related to the Olaregen purchase price
allocation.
|
(f)
|
|
Adjustment
of $149,637 to reduce "Notes payable" to (1) reclassify $140,271 related to
deferred rent against "General and administrative expenses", and (2) to reclass
$9,366 to "Other noncurrent liabilities" related to finance leases.
|
(g)
|
|
Adjustment
of $171,562 to increase "Other noncurrent liabilities" to (1) reclassify $162,196
related leasehold tenant allowance, and (2) $9,366 related to finance leases from "Note
payable - noncurrent" to "Other noncurrent liabilities."
|
(h)
|
|
Adjustment
to reclassify $192,671 from "Derivative liability - convertible notes" to "Derivative
liability - warrants".
|
(i)
|
|
Adjustment
to reclassify $4,033,898 from "Non-controlling interest" to 'Redeemable non-controlling
interest" related to the purchase price allocation of the Regentys acquisition.
|
(j)
|
|
Adjustment
to eliminate $1,815,575 of Regentys Series A Preferred Stock in conjunction
with the revised purchase price allocation of the Regentys acquisition
|
(k)
|
|
Adjustment
to eliminate $1,000,000 of Olaregen Series A Preferred Stock in conjunction
with the revised purchase price allocation of the Olaregen acquisition
|
(l)
|
|
Adjustment
to reduce "Additional paid-in capital" (APIC) of $2,996,116 due to a reduction
of APIC of (1) $2,215,575 related to the Regentys acquisition, and (2) $750,541 related
to the Olaregen acquisition.
|
The
effects of the restatement on the line items within the Company’s condensed interim consolidated statements of operations
and comprehensive income for the six months ended January 31, 2019 are as follows:
GENEREX
BIOTECHNOLOGY CORPORATION AND SUBSIDIARIES
|
UNAUDITED
CONDENSED INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME
|
|
|
|
|
|
|
Six
Months Ended January 31, 2019
|
|
|
As
previously reported
|
|
Adjusted
|
|
|
|
Restated
|
Revenue,
net
|
|
$
|
6,567,942
|
|
|
$
|
(1,406,529
|
)
|
|
|
(a)(b)
|
|
|
$
|
5,161,413
|
|
Total
Revenue
|
|
|
6,567,942
|
|
|
|
(1,406,529
|
)
|
|
|
|
|
|
|
5,161,413
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of Goods Sold
|
|
|
2,882,300
|
|
|
|
—
|
|
|
|
|
|
|
|
2,882,300
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross
Profit
|
|
|
3,685,642
|
|
|
|
(1,406,529
|
)
|
|
|
|
|
|
|
2,279,113
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating expenses
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research
and development
|
|
|
991,005
|
|
|
|
—
|
|
|
|
|
|
|
|
991,005
|
|
General
and administrative
|
|
|
9,868,110
|
|
|
|
(1,096,805
|
)
|
|
|
(b)(a)
|
|
|
|
8,771,305
|
|
Total
operating expenses
|
|
|
10,859,115
|
|
|
|
(1,096,805
|
)
|
|
|
|
|
|
|
9,762,310
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating Loss
|
|
|
(7,173,473
|
)
|
|
|
(309,724
|
)
|
|
|
|
|
|
|
(7,483,197
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other Income (Expense):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest
expense
|
|
|
(2,262,936
|
)
|
|
|
—
|
|
|
|
|
|
|
|
(2,262,936
|
)
|
Interest
income
|
|
|
768
|
|
|
|
—
|
|
|
|
|
|
|
|
768
|
|
Changes
in fair value of contingent purchase consideration (Note 10)
|
|
|
15,147,591
|
|
|
|
—
|
|
|
|
|
|
|
|
15,147,591
|
|
Change
in fair value of derivative liability (Note 12)
|
|
|
142,725
|
|
|
|
—
|
|
|
|
|
|
|
|
142,725
|
|
Impairment
of long-lived assets (Note 10)
|
|
|
(242,139
|
)
|
|
|
142,620
|
|
|
|
(c)
|
|
|
|
(99,519
|
)
|
Other
income, net
|
|
|
(47,436
|
)
|
|
|
—
|
|
|
|
|
|
|
|
(47,436
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net Income
|
|
|
5,565,100
|
|
|
|
(167,104
|
)
|
|
|
|
|
|
|
5,397,996
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss attributable
to noncontrolling interests (Note 7)
|
|
|
(360,403
|
)
|
|
|
—
|
|
|
|
|
|
|
|
(360,403
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net
Income Available to Common Stockholders
|
|
$
|
5,925,503
|
|
|
$
|
(167,104
|
)
|
|
|
|
|
|
$
|
5,758,399
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net Income per Common Share
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
$
|
0.16
|
|
|
$
|
(0.00
|
)
|
|
|
|
|
|
$
|
0.16
|
|
Diluted
|
|
$
|
0.16
|
|
|
$
|
(0.02
|
)
|
|
|
|
|
|
$
|
0.14
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares Used to Compute
Income per Share (Note 6)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
|
36,387,206
|
|
|
|
(0.00
|
)
|
|
|
|
|
|
|
36,387,206
|
|
Diluted
|
|
|
36,387,206
|
|
|
|
(0.00
|
)
|
|
|
|
|
|
|
41,514,648
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Comprehensive Income:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net
Income
|
|
$
|
5,925,503
|
|
|
$
|
(167,104
|
)
|
|
|
|
|
|
$
|
5,758,399
|
|
Change
in foreign currency translation adjustments
|
|
|
2,024
|
|
|
|
—
|
|
|
|
|
|
|
|
2,024
|
|
Comprehensive
Income Available to Common Stockholders
|
|
$
|
5,927,527
|
|
|
$
|
(167,104
|
)
|
|
|
|
|
|
$
|
5,760,423
|
|
(a)
|
|
Revenue
adjustment of $1,406,529 was reduced to eliminate intercompany revenue related to the
Veneto acquisition against "general and administrative expenses."
|
(b)
|
|
General
and administrative expense adjustment of $1,096,805 was primarily due to (1) reduce and
eliminate an intercompany account related to the Veneto acquired operations against "revenues"
for $1,406,529, (2) a $17,367 decrease in "General and administrative expenses"
to record interest expense originating from the Veneto acquired operations and increase
"cash", (3) adjustment to correct and remove deferred rent expense of $21,925
recorded against rent expense related to the Veneto acquired assets, and (4) adjustment
to recognize $305,166 amortization expense on Veneto intangible assets acquired in November
3, 2018 "Second Closing."
|
(c)
|
|
Reclassification
and reduction of "Impairment of goodwill" to "Impairment of long-lived
assets" of $142,620 related to the closing of the Grainland Pharmacy.
|
The
effects of the restatement on the line items within the Company’s condensed interim consolidated statement of cash flow
as of January 31, 2019 are as follows:
GENEREX
BIOTECHNOLOGY CORPORATION AND SUBSIDIARIES
|
UNAUDITED
CONDENSED INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS
|
|
|
|
|
January
31, 2019
|
|
|
|
As
previously reported
|
|
|
|
Adjusted
|
|
|
|
Restated
|
|
CASH
FLOWS FROM OPERATING ACTIVITIES
|
|
|
|
|
|
|
|
|
|
|
|
|
Net Income
|
|
$
|
5,565,100
|
|
|
$
|
(167,104
|
)
|
|
$
|
5,397,996
|
|
Adjustments to reconcile
net income to net cash used in operating activities:
|
|
|
|
|
|
|
|
|
|
|
|
|
Depreciation
and amortization
|
|
|
73,034
|
|
|
|
305,166
|
|
|
|
378,200
|
|
Issuance
of stock options as compensation
|
|
|
924,845
|
|
|
|
—
|
|
|
|
924,845
|
|
Changes
in fair value of contingent purchase consideration
|
|
|
(15,147,591
|
)
|
|
|
—
|
|
|
|
(15,147,591
|
)
|
Change
in fair value of derivative liabilities - convertible notes
|
|
|
202,500
|
|
|
|
(380,344
|
)
|
|
|
(177,844
|
)
|
Change
in fair value of derivative liabilities - warrants
|
|
|
—
|
|
|
|
35,119
|
|
|
|
35,119
|
|
Impairment
of long-lived assets
|
|
|
—
|
|
|
|
99,519
|
|
|
|
99,519
|
|
Changes in operating
assets and liabilities:
|
|
|
|
|
|
|
|
|
|
|
|
|
Accounts
receivable
|
|
|
516,822
|
|
|
|
170,067
|
|
|
|
686,889
|
|
Inventory
|
|
|
389,924
|
|
|
|
(3,937
|
)
|
|
|
385,987
|
|
Accounts
payable and accrued expenses
|
|
|
3,285,385
|
|
|
|
11,245
|
|
|
|
3,296,630
|
|
Accrued
interest on notes receivable
|
|
|
(18,288
|
)
|
|
|
—
|
|
|
|
(18,288
|
)
|
Other
current assets
|
|
|
9,094
|
|
|
|
(6,158
|
)
|
|
|
2,936
|
|
Other
assets, net
|
|
|
(10,997
|
)
|
|
|
—
|
|
|
|
(10,997
|
)
|
Other
current liabilities
|
|
|
—
|
|
|
|
4,620
|
|
|
|
4,620
|
|
Other
noncurrent liabilities
|
|
|
—
|
|
|
|
171,562
|
|
|
|
171,562
|
|
Net
used in operating activities
|
|
|
(4,210,172
|
)
|
|
|
239,755
|
|
|
|
(3,970,417
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CASH
FLOWS FROM INVESTING ACTIVITIES:
|
|
|
|
|
|
|
|
|
|
|
|
|
Purchase
of property and equipment
|
|
|
(10,070
|
)
|
|
|
(16,601
|
)
|
|
|
(26,671
|
)
|
Purchase
of intangible assets
|
|
|
—
|
|
|
|
(26,488
|
)
|
|
|
(26,488
|
)
|
Disposal
of property and equipment
|
|
|
(5,393
|
)
|
|
|
5,393
|
|
|
|
—
|
|
Issuance
of note payable
|
|
|
13,986
|
|
|
|
(13,986
|
)
|
|
|
—
|
|
Cash
received in acquisition of a business
|
|
|
1,722,814
|
|
|
|
—
|
|
|
|
1,722,814
|
|
Net
cash provided by (used in) investing activities
|
|
|
1,721,337
|
|
|
|
(51,682
|
)
|
|
|
1,669,655
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CASH
FLOWS FROM FINANCING ACTIVITIES
|
|
|
|
|
|
|
|
|
|
|
|
|
Loan
proceeds from related party
|
|
|
(3,305
|
)
|
|
|
—
|
|
|
|
(3,305
|
)
|
Payment
of notes payable
|
|
|
(28,011
|
)
|
|
|
(629
|
)
|
|
|
(28,640
|
)
|
Proceeds
from note payable
|
|
|
3,524,460
|
|
|
|
—
|
|
|
|
3,524,460
|
|
Investment
in subsidiary by noncontrolling interest
|
|
|
133,679
|
|
|
|
—
|
|
|
|
133,679
|
|
Net
cash provided by financing activities
|
|
|
3,626,823
|
|
|
|
(629
|
)
|
|
|
3,626,194
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Effects
of currency translation on cash and cash equivalents
|
|
|
2,024
|
|
|
|
—
|
|
|
|
2,024
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net
increase (decrease) in cash and cash equivalents
|
|
|
1,140,012
|
|
|
|
187,444
|
|
|
|
1,327,456
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash
and cash equivalents, beginning of period
|
|
|
1,046,365
|
|
|
|
—
|
|
|
|
1,046,365
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash
and cash equivalents, end of period
|
|
$
|
2,186,377
|
|
|
$
|
187,444
|
|
|
$
|
2,373,821
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Supplemental
Disclosure of Cash Flow Information
|
|
|
|
|
|
|
|
|
|
|
|
|
Acquisition
of Veneto assets & liabilities - First Closing
|
|
$
|
—
|
|
|
$
|
(13,947,462
|
)
|
|
$
|
(13,947,462
|
)
|
Acquisition
of Veneto assets & liabilities - Second Closing
|
|
$
|
—
|
|
|
$
|
(19,948,909
|
)
|
|
$
|
(19,948,909
|
)
|
Acquisition
of Regentys assets & liabilities
|
|
$
|
—
|
|
|
$
|
(337,538
|
)
|
|
$
|
(337,538
|
)
|
Acquisition
of Olaregen assets & liabilities
|
|
$
|
—
|
|
|
$
|
212,355
|
|
|
$
|
212,355
|
|
Extinguishment
of HDS debt
|
|
$
|
—
|
|
|
$
|
(14,056,109
|
)
|
|
$
|
(14,056,109
|
)
|
Note
payable issued for acquisition of a business
|
|
$
|
—
|
|
|
$
|
35,000,000
|
|
|
$
|
35,000,000
|
|
Discounts
on note payable and convertible debt
|
|
$
|
—
|
|
|
$
|
165,833
|
|
|
$
|
165,833
|
|
Market
value of convertible notes
|
|
$
|
—
|
|
|
$
|
(2,110,000
|
)
|
|
$
|
(2,110,000
|
)
|
Derivative
liability - convertible notes
|
|
$
|
—
|
|
|
$
|
2,530,983
|
|
|
$
|
2,530,983
|
|
Derivative
liability - convertible warrants
|
|
$
|
—
|
|
|
$
|
157,552
|
|
|
$
|
157,552
|
|
Conversion
of series H 9% convertible preferred stock to common stock
|
|
$
|
—
|
|
|
$
|
25,200
|
|
|
$
|
25,200
|
|
Conversion
of series I 9% convertible preferred stock to common stock
|
|
$
|
—
|
|
|
$
|
6,631
|
|
|
$
|
6,631
|
|
Note
3 – Summary of Significant Accounting Policies:
Revenue
Recognition
—Revenue is recognized when: (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred
or services have been rendered, (iii) the seller’s price to the buyer is fixed or determinable, and (iv) collectability
is reasonably assured.
Revenue
from the provision of pharmacy services is recognized when the prescription is dispensed (picked up by the patient or shipped
to the patient using common carrier or delivered by the pharmacies own personnel). At the time of dispensing each pharmacy has
a contract with the insurance payor (item (i)); the insurance payor has accepted the claim for reimbursement from the pharmacy
and informed the pharmacy how much will be paid for the prescription (item (iii)); the insurance payor is now legally obligated
to make payment on the accepted claim within a given period proscribed by statute (item (iv)); and, the prescription has been
taken from the pharmacy inventory, placed into an individually labeled container specific to the patient, and the patient is able
to take possession of the prescription (item (ii)). Shipment to or pick up by the patient is the first time that all criteria
for revenue recognition have been met.
Revenue
from the provision of laboratory services is recognized upon the completion of accessions (the requested laboratory test has been
performed and the report has been issued to the requesting physician). After the test has been performed and reported, the insurance
company and/or patient has an obligation to pay for medically necessary laboratory tests (items (i) and (ii)). Unlike the pharmacy
services model, laboratory services are provided prior to insurance company approval; as a result, the seller’s price to
buyer is not known until payment is provided (items (iii) and (iv). Based on historical collections, the Company estimates the
expected revenues associated with similar tests and recognizes the revenue when testing results have been provided.
Provisions
for estimated sales returns and uncollectible accounts are recorded in the period in which the related sales are recognized based
on historical and anticipated rates.
The
Company determines whether it is the principal or agent for its retail pharmacy contract services on a contract by contract basis.
In the majority of its contracts, the Company has determined it is the principal due to it: (i) being the primary obligor in the
arrangement, (ii) having latitude in changing the product or performing part of the service, (iii) having discretion in supplier
selection, (iv) having involvement in the determination of product or service specifications, and (v) having credit risk. The
Company’s obligations under its client contracts for which revenues are reported using the gross method are separate and
distinct from its obligations to the third-party pharmacies included in its retail pharmacy network contracts. Pursuant to these
contracts, the Company is contractually required to pay the third-party pharmacies in its retail pharmacy network for products
sold, regardless of whether the Company is paid by its clients. The Company’s responsibilities under its client contracts
typically include validating eligibility and coverage levels, communicating the prescription price and the co-payments due to
the third-party retail pharmacy, identifying possible adverse drug interactions for the pharmacist to address with the prescriber
prior to dispensing, suggesting generic alternatives where clinically appropriate, and approving the prescription for dispensing.
Although the Company does not have credit risk with respect to Retail Co-Payments or inventory risk related to retail network
claims, management believes that all of the other applicable indicators of gross revenue reporting are present. For contracts
under which the Company acts as an agent, revenue is recognized using the net method.
Cost
of Goods Sold
—Costs and directly related expenses to sell the Company’s products and services are recorded as
cost of goods sold when the related revenue is recognized. The Company records shipping and handling costs related to delivery
of products to customers within cost of goods sold.
Inventories
—Inventories,
which consist of finished goods, are stated at the lower of cost, determined principally under the first-in, first-out method,
or net realizable value. Inventories include the cost of pharmaceuticals, reagents, and consumables. Obsolete or excess inventories
are reflected at their estimated realizable values. Net realizable value is the estimated sales revenue for a normal period of
activity less expected selling costs. Allowances for excess and obsolete inventory are recognized for excess amounts, obsolescence
and declines in net realizable value below cost. Estimation and judgment are required in determining the value of the allowance
for excess and obsolete inventory at each statement of financial position date. Management specifically analyzes estimates of
future demand for products when determining allowances for excess and obsolete inventory. Changes in these estimates could result
in revisions to the valuation of inventory in future periods.
Property
and Equipment
—Property, equipment and improvements to leased premises are depreciated using the straight-line method
over the estimated useful lives of the assets, or when applicable, the term of the lease, whichever is shorter. Major renewals
or replacements that substantially extend the useful life of an asset are capitalized and depreciated. Property and equipment
are depreciated using the straight-line method over the estimated useful lives of the assets, which are generally as follows:
Leasehold improvements
|
The shorter
of the expected useful life of the improvement or the lease term
|
|
|
Computers and technological assets
|
3-5 years
|
Machinery and equipment
|
5 years
|
Furniture and fixtures
|
7 years
|
Assets
acquired through finance lease arrangements or long-term rental arrangements that transfer substantially all the risks and rewards
associated with ownership of the asset to the Company (as lessee) are capitalized.
Reclassifications
to Prior Period Financial Statements and Adjustments
Certain
reclassifications have been made in the Company’s condensed interim consolidated financial statements of the prior year
to conform to the current year presentation. These reclassifications have no impact on previously reported net income.
Redeemable
Non-Controlling Interest
As
a result of the acquisition of Regentys with redeemable convertible preferred stock classified as a mezzanine instrument outside
of the its equity accounts, such amounts are reclassified as redeemable non-controlling interest as the carrying value determined
by the purchase price allocation at the time of the acquisition of Regentys.
Derivative
Financial Instruments
As
a result of the adoption of ASU 2017-11 in the second quarter, the Company has no derivative financials instruments with down
round features classified as a liability at January 31, 2019.
Adoption
of New Accounting Standards
We
have reviewed the FASB issued Accounting Standards Update (“ASU”) accounting pronouncements and interpretations thereof
that have effective dates during the periods reported and in future periods. The Company has carefully considered the new pronouncements
that alter previous generally accepted accounting principles and does not believe that any new or modified principles will have
a material impact on the Company’s reported financial position or operations in the near term. The applicability of any
standard is subject to the formal review of our financial management and certain standards are under consideration.
•
|
|
ASU
2014-09, “Revenue from Contracts with Customers (Topic 606)”
|
|
|
|
•
|
|
ASC 815-40 (formerly SFAS No. 133 “Accounting for derivative
instruments and hedging activities”), requires that embedded derivative instruments be bifurcated and assessed, along
with free-standing derivative instruments such as warrants, on their issuance date and in accordance with ASC 815-40-15 (formerly
EITF-00-19 “Accounting for derivative financial instruments indexed to, and potentially settled in, a company’s
own stock”) to determine whether they should be considered a derivative liability and measured at their fair value for
accounting purposes. In determining the appropriate fair value, the Company uses the Black-Scholes option pricing formula
and present value pricing. At January 31, 2019, the Company adjusted its derivative liability to its fair value, and reflected
the change in fair value, in its condensed interim consolidated statement of operations and comprehensive loss.
|
•
|
|
ASU
2016-08 “Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue
Gross versus Net).”
|
•
|
|
ASU
2016-10, “Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing.”
|
•
|
|
ASU
2016-11, “Revenue Recognition (Topic 605) and Derivatives and Hedging (Topic 815): Rescission of SEC Guidance Because
of Accounting Standards Updates 2014-09 and 2014-16 Pursuant to Staff Announcements at the March 3, 2016 EITF (Emerging Issue
Task Force) Meeting.”
|
•
|
|
ASU
2016-12, “Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients.”
|
•
|
|
ASU
2016-20, “Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers.”
|
•
|
|
ASU
2017-13, “Revenue Recognition (Topic 605), Revenue from Contracts with Customers (Topic 606), Leases (Topic 840) and
Leases (Topic 842). Amendments to SEC Paragraphs Pursuant to the Staff Announcement at the July 20, 2017 EITF Meeting and
Rescission of Prior SEC Staff Announcements and Observer Comments.”
|
The
standards provide companies with a single model for use in accounting for revenue arising from contracts with customers that supersedes
current revenue recognition guidance, including industry-specific revenue guidance. The core principle of the model is to recognize
revenue when control of the goods or services transfers to the customer, as opposed to recognizing revenue when the risks and
rewards transfer to the customer under the existing revenue guidance. The guidance permits companies to either apply the requirements
retrospectively to all prior periods presented, or apply the requirements in the year of adoption, through a cumulative adjustment. The
guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017. The
guidance was adopted as of August 1, 2018. The Company performed a cumulative adjustment and found that the adoption did not have
a material effect on the Company’s condensed interim consolidated financial statements and related disclosures.
In
January 2016, the FASB issued ASU No. 2016-01,
Financial Instruments—Overall: Recognition and Measurement of Financial
Assets and Financial Liabilities
(“ASU 2016-01”). This standard affects the accounting for equity instruments,
financial liabilities under the fair value option and the presentation and disclosure requirements of financial instruments. In
February 2018, the FASB issued ASU 2018-03, “Technical Corrections and Improvements to Financial Instruments (Subtopic 825-10)
– Recognition and Measurement of Financial Assets and Financial Liabilities”. This update was issued to clarify certain
narrow aspects of guidance concerning the recognition of financial assets and liabilities established in ASU No. 2016-01, “Financial
Instruments—Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities”. This
includes an amendment to clarify that an entity measuring an equity security using the measurement alternative may change its
measurement approach to a fair valuation method in accordance with Topic 820, Fair Value Measurement, through an irrevocable election
that would apply to that security and all identical or similar investments of the same issued. The update is effective for fiscal
years beginning after December 15, 2017 and interim periods within those fiscal years beginning after June 15, 2018. The guidance
was adopted as of August 1, 2018 and did not have a material effect on the Company’s condensed interim consolidated financial
statements and related disclosures.
In
August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and
Cash Payments (“ASU 2016-15”). ASU 2016-15 addresses eight specific cash flow issues with the objective of reducing
diversity in practice regarding how certain cash receipts and cash payments are presented in the statement of cash flows. The
standard provides guidance on the classification of the following items: (1) debt prepayment or debt extinguishment costs, (2)
settlement of zero-coupon debt instruments, (3) contingent consideration payments made after a business combination, (4) proceeds
from the settlement of insurance claims, (5) proceeds from the settlement of corporate-owned life insurance policies, (6) distributions
received from equity method investments, (7) beneficial interests in securitization transactions, and (8) separately identifiable
cash flows. The Company is required to adopt ASU 2016-15 for fiscal years, and for interim periods within those fiscal years,
beginning after December 15, 2017 on a retrospective basis. The guidance was adopted as of August 1, 2018 and did not have a material
effect on the Company’s condensed interim consolidated financial statements and related disclosures.
In
November 2016, the FASB issued ASU 2016-18,
Statement of Cash Flows (Topic 230): Restricted Cash,
which requires that a
statement of cash flows should include the total of cash, cash equivalents, and amounts generally described as restricted cash
or restricted cash equivalents when reconciling the beginning-of-period and end-of-period total amounts. The update is effective
for fiscal years beginning after December 15, 2017. The guidance was adopted as of August 1, 2018 and did not have a material
effect on the Company’s condensed interim consolidated financial statements and related disclosures.
In
January 2017, the FASB issued ASU 2017-01, “Business Combinations (Topic 805): Clarifying the Definition of a Business.”
These amendments clarify the definition of a business. The amendments affect all companies and other reporting organizations that
must determine whether they have acquired or sold a business. The definition of a business affects many areas of accounting including
acquisitions, disposals, goodwill, and consolidation. The amendments are intended to help companies and other organizations evaluate
whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. This update is effective
for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017. The guidance was adopted as
of August 1, 2018 and did not have a material effect on the Company’s condensed interim consolidated financial statements
and related disclosures.
In
May 2017, the FASB issued ASU 2017-09, “Compensation-Stock Compensation” (Topic 718): Scope of Modification Accounting.
The amendments provide guidance on determining which changes to the terms and conditions of share-based payment awards require
an entity to apply modification accounting under Topic 718 Compensation-Stock Compensation. An entity should account for the effects
of a modification unless all the following are met: 1. The fair value (or calculated value or intrinsic value, if such an alternative
measurement method is used) of the modified award is the same as the fair value (or calculated value or intrinsic value, if such
an alternative measurement method is used) of the original award immediately before the original award is modified. If the modification
does not affect any of the inputs to the valuation technique that the entity uses to value the award, the entity is not required
to estimate the value immediately before and after the modification. 2. The vesting conditions of the modified award are the same
as the vesting conditions of the original award immediately before the original award is modified. 3. The classification of the
modified award as an equity instrument or a liability instrument is the same as the classification of the original award immediately
before the original award is modified. The ASU is effective for all entities for annual periods, including interim periods within
those annual periods, beginning after December 15, 2017. The guidance was adopted as of August 1, 2018 and did not have a material
effect on the Company’s condensed interim consolidated financial statements and related disclosures.
Recently
Issued Accounting Standards
In
February 2016, the FASB issued ASU No. 2016-02,
Leases
(“ASU 2016-02”). In January 2018, the FASB
issued ASU 2018-01, which provides additional implementation guidance on the previously issued ASU 2016-02. Under the new guidance,
lessees will be required to recognize the following for all leases (with the exception of short-term leases) at the commencement
date: (1) a lease liability, which is a lessee's obligation to make lease payments arising from a lease, measured on a discounted
basis; and (2) a right-of-use asset, which is an asset that represents the lessee's right to use, or control the use of, a specified
asset for the lease term. The Company is required to adopt ASU 2016-02 for fiscal years, and for interim periods within those
fiscal years, beginning after December 15, 2018. The Company does not plan to elect early adoption for this pronouncement.
In
January 2017, the FASB issued ASU 2017-04,
Simplifying the Test for Goodwill Impairment
(Topic 350), which eliminates
Step 2 from the goodwill impairment test. Instead, an entity should perform its annual or interim goodwill impairment test by
comparing the fair value of a reporting unit with its carrying amount and recognize an impairment charge for the amount by which
the carrying amount exceeds the reporting unit's fair value, not to exceed the total amount of goodwill allocated to the reporting
unit. The Company will adopt the standard effective October 1, 2020. The Company is evaluating the effect that ASU 2017-04 will
have on its condensed interim consolidated financial statements.
In
July 2017, the FASB issued ASU 2017-11,
Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic
480) and Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments with Down Round Features; II. Replacement
of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily
Redeemable Non-controlling Interests with a Scope Exception.
Part I of this update addresses the complexity
of accounting for certain financial instruments with down round features. Down round features are features of certain equity-linked
instruments (or embedded features) that result in the strike price being reduced on the basis of the pricing of future equity
offerings. Current accounting guidance creates cost and complexity for entities that issue financial instruments (such as warrants
and convertible instruments) with down round features that require fair value measurement of the entire instrument or conversion
option. Part II of this update addresses the difficulty of navigating
Topic 480, Distinguishing Liabilities from
Equity
, because of the existence of extensive pending content in the FASB Accounting Standards Codification. This pending
content is the result of the indefinite deferral of accounting requirements about mandatorily redeemable financial instruments
of certain nonpublic entities and certain mandatorily redeemable non-controlling interests. The amendments in Part II
of this update do not have an accounting effect. This ASU is effective for interim and annual reporting periods beginning after
December 15, 2018. Early adoption is permitted, including adoption in an interim period. The Company early adopted the ASU
2017-11 in the second quarter as of January 31, 2019.
In
February 2018, the FASB issued ASU 2018-02,
Income Statement – Reporting Comprehensive Income (Topic 220):
Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income
, which was issued to address the income
tax accounting treatment of the stranded tax effects within other comprehensive income due to the prohibition of backward tracing
due to an income tax rate change that was initially recorded in other comprehensive income. This issue came about from the enactment
of the TCJA on December 22, 2017 that changed the Company’s federal income tax rate from 35% to 21%. The ASU changed
current accounting whereby an entity may elect to reclassify the stranded tax effect from accumulated other comprehensive income
to retained earnings. The amendments in this ASU are effective for interim and annual reporting periods beginning after December 15,
2018. Early adoption is permitted, including adoption in an interim period. Adoption of this ASU is to be applied either in the
period of adoption or retrospectively to each period in which the effect of the change in the tax laws or rates were recognized.
The Company is currently evaluating the impact, if any, ASU 2018-02 will have on its financial position, results of
operations, and its consolidated financial statement disclosures. The Company’s evaluation process includes, but is not
limited to, identifying transactions and accounts within the scope of the guidance, reviewing its accounting and disclosures for
these transactions and accounts, and identifying and implementing any necessary changes to its accounting and disclosures as a
result of the guidance. The Company is evaluating the effect that ASU 2018-02 will have on its condensed interim consolidated
financial statements.
In
August 2018, the FASB issued ASU 2018-13, “Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure
Requirements for Fair Value Measurement”, which adds disclosure requirements to Topic 820 for the range and weighted average
of significant unobservable inputs used to develop Level 3 fair value measurements. This ASU is effective for interim and annual
reporting periods beginning after December 15, 2019. The Company is evaluating the effect that ASU 2018-13 will have on its condensed
interim consolidated financial statements.
Note
4 - Loans from Related Parties
HDS
received substantially all of its funding from a shareholder, who owned 98.9% of HDS prior to the acquisition of HDS by the Company.
The loan is unsecured, matures on December 31, 2019 and accrued interest at 0.75% per annum through January 19, 2017, and bears
no interest thereafter. Upon acquisition of HDS by the Company (see Note 10), the outstanding principal balance was $13,239,837
and total accrued interest of $191,869. This loan was subject to a call option (Note 10) which, if exercised, the principal and
accrued interest through January 18, 2017 would be eliminated.
Pursuant
to the January 18, 2017 Acquisition, Mr. Berkman agreed, under certain conditions to transfer the remaining 49% of the HDS equity
to the Company for a consideration of $1.00. On December 1, 2018, the Company and Mr. Berkman entered into an Agreement, Assignment
and Release, pursuant to which Mr. Berkman transferred the remaining HDS equity interests to the Company, waiving and releasing
any conditions to such transfer. HDS is now a wholly owned subsidiary of the Company. In addition to the assignment of the HDS
interests, Mr. Berkman released these loans in exchange for shares of the Company’s common stock valued at the aggregate
of such amount using the closing price for the common stock on November 30, 2018. The closing price was $18.99, resulting in 32,881
shares issuable to Mr. Berkman. This transaction resulted in $624,404 plus the loan and call option which resulted in additional
paid in capital of $13,431,705 which was reclassified to the Company’s stockholders’ equity as an extinguishment of
debt for $14,056,109.
Pursuant
to the January 7, 2019 acquisition of Regentys Corporation (“Regentys”), the Company acquired $16,505 of loans payable
to Regentys shareholders which had a principal balance of $13,200 as of January 31, 2019.
Note
5 - Commitments and Contingencies:
Pending
Litigation
The
Company is a defendant in one legal proceeding relating to alleged breach of contract and claims against certain of the Company’s
original buccal delivery patents. The Company is also a defendant in two legal proceedings brought by a former executive officer
and her affiliate. These legal proceedings have been reported in the Company’s prior periodic reports. No activity has occurred
in these cases in several years, and the Company now considers them dormant.
In
December 2011, a vendor of the Company commenced an action against the Company and its subsidiary, Generex Pharmaceuticals, Inc.,
in the Ontario Superior Court of Justice claiming damages for unpaid invoices including interest in the amount of $429,000, in
addition to costs and further interest. The Company responded to this statement of claim and also asserted a counterclaim
in the proceeding for $200,000 arising from the vendor’s breach of contract and detinue, together with interest and costs.
On November 16, 2012, the parties agreed to settle this action and the Company has agreed to pay the plaintiff $125,000, following
the spinout of its subsidiary Antigen, from the proceeds of any public or private financing related to Antigen subsequent to such
spinout. Each party agreed to execute mutual releases to the claim and counterclaim to be held in trust by each party’s
counsel until payment of the settlement amount. Following payment to the plaintiff, the parties agree that a Consent Dismissal
Order without costs will be filed with the court. If the Company fails to make the payment following completion of any post-spinout
financing related to Antigen or any other subsidiaries, the Plaintiffs may take out a judgment in the amount of the claim plus
interest of 3% per annum and costs fixed at $25,000. This has been accrued in the unaudited condensed interim consolidated financial
statements.
On
August 22, 2017, Generex received a letter from counsel for Three Brothers Trading LLC, d/b/a Alternative Execution Group (“AEXG”),
claiming breach of a Memorandum of Understanding (“MOU”) between Generex and AEXG. The MOU related to AEXG referring
potential financing candidate to Generex. The letter from AEXG counsel claimed that Generex’s acceptance of $3,000,000
in financing from Pharma Trials, LLC, in March 2017, violated the provisions of the MOU prohibiting Generex from seeking other
financing, with certain exceptions, for a period of 60 days after execution of the MOU. AEXG has demanded at least $210,000 in
cash and 84,000 warrants for Generex stock convertible at $2.50 per share, for attorney’s fees and costs. On December 2,
2018, an arbitrator awarded Three Brothers Trading LLC, d/b/a Alternative Execution Group (“AEXG”) an aggregate of
$315,695 in damages, costs and fees as well as warrants exercisable for 84,000 shares of Generex Common Stock at an exercise price
of $2.50 per share. The awards were made pursuant to claims under a Memorandum of Understanding (“MOU”) between Generex
and AEXG related to AEXG referring potential financing candidate to Generex. AEXG filed a petition to confirm the arbitrator’s
award in the United States District Court for the Southern District of New York. The petition includes a demand of $3,300,360
as the value of the Warrants. The arbitrator did not award the specific amount of $3.3 million, but only liquidated damages in
the amount of $220,000 and the value of 84,000 warrants “as of today” (the date of the award) plus attorney’s
fees, certain costs, prejudgment and post-judgment interest (which continues to run on a daily basis) and arbitration fees. Generex
has responded that the value of the warrants on the date of the award is $0 or some figure far less than the value calculated
by AEXG. The petition to confirm the arbitrator’s award and Generex’s opposition are pending before the Court for
a decision. The Company has not recorded any accrual related to this matter.
On
June 28, 2018, the Company was named in respect of a claim by Burrard Pharmaceutical Enterprises Ltd. and Moa’yeri Kayhan
for unspecified damages and other remedies issued by the Supreme Court of British Columbia. The claim is made in connection with
one advanced against Burrard and Kayhan by Middle East Pharmaceutical Factory L.L.C., a foreign corporation, for fraudulent or
negligent misrepresentation. Middle East alleges that it was misled by Burrard and Kayhan into believing that Burrard had rights
to distribute Generex product in the Middle East. Burrard and Kayhan allege that they did have rights in that regard, which the
Company denies. The matter remains at the pleadings stage and the Company is investigating the facts.
On
October 26, 2018, Generex entered into a Securities Purchase Agreement with an investor pursuant to which the Company agreed to
sell and sold its Note Due October 26, 2019 (“Note”) in the principal amount of $682,000
.
On January 25, 2018,
Generex received a letter from the purchaser’s counsel stating that the Note was in default because Generex’s common
stock was not listed on NASDAQ within 90 days after the issuance of the Note. The letter demanded repayment in full. On February
12, 2019, the Purchaser filed a Motion for Summary Judgment in lieu of complaint in the Supreme Court of New York, demanding
the aggregate principal amount, default interest and costs. Counsel for Generex and Alpha have engaged in settlement discussions
which are likely to result in an agreement by Generex to pay an amount more than the existing note payable balance of $600,000
but less than the full amount demanded over a period of four months.
Line
of Credit
In
connection with the second closing of the acquisition of certain operating assets of Veneto Holdings, L.L.C. and its affiliates,
Generex’s wholly owned subsidiary agreed to assume outstanding debt of Veneto subsidiaries to Compass Bank, including obligations
under a term loan and a revolving line of credit. Claiming three separate types of default, Compass Bank has demanded payment
in full of amounts due under the term loan and revolving line of credit, in an aggregate amount of approximately $3,413,000. Generex
believes it has defenses to such demand, including that the bank was not an intended beneficiary of the subsidiary’s agreement
to assume the debt.
With
respect to all litigation, as additional information concerning the estimates used by the Company becomes known, the Company reassesses
its position both with respect to accrued liabilities and other potential exposures.
Commitments
Lease
Agreements
There
are rental agreements in effect at Hema Diagnostics Systems, Grainland Pharmacy Inc., Empire State Pharmacy Inc., Veneto Holdings,
L.L.C., Regentys Corporation and Olaregen Therapeutix Inc. and paid out in the following periods: $360,843 in fiscal year 2019,
$399,390 in fiscal year 2020, $184,298 in fiscal year 2021, $120,794 in fiscal year 2022 and $2,774 in fiscal year 2023.
Intellectual
Property
In
connection with the Company’s acquisition of Olaregen, intellectual property was acquired that had a valuation of $650,000
prior to being acquired and revalued. This initial $650,000 valuation represented the initial payment remitted by Olaregen in
accordance with the $4 million signed commitment agreement entered into with Activation Therapeutics, Inc. The remaining $3.35
million balance is to be paid in quarterly installments equal to 10% of quarterly net sales generated by Activation Therapeutics
assuming the Exellagen average selling price per unit exceeds $800. In the event that the average selling price per unit is less
than $800 per unit, cost of goods sold shall be excluded from the computation of net sales.
Note
6 - Net Income Per Share (“EPS”):
Basic
net income or loss per share is calculated using the weighted average number of common shares outstanding during the period. Diluted
net income per share is calculated by dividing income available to common shareholders by the weighted average number of common
shares outstanding for the period and, when dilutive, potential shares from stock options and warrants to purchase common stock,
using the treasury stock method. Common stock equivalents are included in the diluted income per share calculation only when option
exercise prices are lower than the average market price of the common shares for the period presented.
The
weighted average number of common stock equivalents not included in diluted income per share, because the effects are anti-dilutive,
was 17,850 for the three and six months ended January 31, 2019.
|
|
Three
Months Ended
January
31,
|
|
Three
Months Ended
January
31,
|
|
|
2019
|
|
2018
|
Weighted average number of
common shares outstanding - Basic
|
|
|
49,967,615
|
|
|
|
22,430,121
|
|
Potentially
dilutive common stock equivalents
|
|
|
5,127,472
|
|
|
|
32,085,329
|
|
Weighted average
number of common and equivalent shares outstanding-Diluted
|
|
|
55,095,087
|
|
|
|
54,515,450
|
|
|
|
Six
Months Ended
January
31,
|
|
Six
Months Ended
January
31,
|
|
|
2019
|
|
2018
|
Weighted average number of
common shares outstanding - Basic
|
|
|
36,387,206
|
|
|
|
22,430,121
|
|
Potentially
dilutive common stock equivalents
|
|
|
5,127,472
|
|
|
|
32,085,329
|
|
Weighted average
number of common and equivalent shares outstanding-Diluted
|
|
|
41,514,678
|
|
|
|
54,515,450
|
|
Note
7 - Stockholders’ Equity:
Common
Stock
On
November 13, 2018, the Company declared a stock dividend on its outstanding Common Stock for stockholders of record date to be
determined (the “Record Date”). As a result, all stockholders on the Record Date received twenty new shares of Common
Stock for each share of Common Stock owned by them as of that date. Proportional adjustments for the reverse stock split were
made to the Company’s outstanding stock options, and warrants including all share and per-share data, for all amounts and
periods presented in the condensed interim consolidated financial statements.
On
January 18, 2017, the Company issued 1,117,431 shares of common stock for the acquisition of 51% of HDS and is obligated to issue
4,830,000 shares of common stock upon the conclusion of the Company’s reverse stock split. On October 26, 2018, 4,830,000
shares were issued.
During
January 2017, the Company issued 168,000 shares of common stock for the conversion of 120 shares of Series F convertible preferred
stock, plus 88,935 shares for the related make-whole payments issued to convert the accumulated dividend payable.
During
January 2017, the Company issued 210,000 shares of common stock for the conversion of 150 shares of Series G convertible preferred
stock, plus 98,448 shares for the related make-whole payments issued to convert the accumulated dividend payable.
During
February 2017, the Company issued 489,993 shares of common stock for the conversion of 350 shares of Series G convertible preferred
stock, plus 222,726 shares for the related make-whole payments issued to convert the accumulated dividend payable.
On
February 9, 2017, the Company offered all current warrant holders an option to exercise immediately all outstanding common stock
purchase warrants on a cashless basis at a reduced exercise price of $0.35 per share from $0.71 per share. The Company agreed
to issue a total of 2,179,989 shares of common stock in connection with the exercise of 6,607,629 warrants in connection with
the following outstanding warrants:
|
|
Warrants
Exercised
|
|
Shares
Agreed to be Issued
|
Series C 9% Convertible Preferred
Stock
|
|
|
210,000
|
|
|
|
69,279
|
|
Series D 9% Convertible Preferred Stock
|
|
|
349,629
|
|
|
|
115,332
|
|
Series E 9% Convertible Preferred Stock
|
|
|
2,513,007
|
|
|
|
829,101
|
|
Series F 9% Convertible Preferred Stock
|
|
|
2,904,993
|
|
|
|
958,419
|
|
Series G 9% Convertible
Preferred Stock
|
|
|
630,000
|
|
|
|
207,858
|
|
|
|
|
6,607,629
|
|
|
|
2,179,989
|
|
During
the six months ended January 31, 2019, 1,238,517 common stock payable was issued. As at January 31, 2019, 349,545 shares remain
to be issued resulting in common stock payable $201,294.
Series
H and Series I Convertible Preferred Stock
The
Company has authorized 109,000 shares of designated non-voting Series H Convertible Preferred Stock with a stated value of $1,000
per share and authorized 6,000 shares of designated non-voting Series I Convertible Preferred Stock with a stated value of $47.61
per share pursuant to the Purchase Agreement dated March 27, 2017. The Series H Preferred Stock was scheduled to be sold in four
tranches to the Purchaser. Under the Securities Purchase Agreement, in the event the Purchaser failed to purchase 100% of the
shares of Preferred Stock at any given Closing, the Company can decline to sell any further securities to the Purchaser (the “Purchase
Agreement”).
The
Series H and Series I Convertible Preferred Stock are convertible at the option of the holder at any time into shares of the Company’s
common stock at an effective conversion price of $.12 per share. An aggregate of 966,000,000 shares of the Company’s common
stock would be issuable upon conversion of both the Series H and Series I Preferred Stock if all shares of such preferred stock
contemplated by the securities purchase agreement are issued.
Neither
Series H nor Series I Convertible Preferred Stock have special dividend rights. If the Company pays dividends on its common stock,
the holders of the preferred stock will receive dividends in the amount they would have received had they converted the preferred
stock to common stock.
At
closing of the first tranche on March 28, 2017, the Company issued 63,000 shares of Series H Preferred Stock for a purchase price
of $3,000,000. The proceeds of this sale were paid directly on the Company’s behalf to Emmaus as an additional deposit under
the Company’s Emmaus LOI. The full amount of such proceeds was repaid to the Company in July 2017 upon termination of the
Emmaus LOI. On December 1, 2018, after payment of the dividend, B-H Sanford, LLC, converted all of its holding of the Company’
Series H Convertible Preferred Stock owned by it into 25,200,000 shares of common stock.
Prior
to payment of Generex’s 20 for 1 common stock dividend, on November 30, 2018, Joseph Moscato, the Company’s President
and Chief Executive Officer, and Lawrence Salvo, a member of the Company’s Board of Directors, converted all shares
of the Company’ Series I Convertible Preferred Stock owned by them. Mr. Moscato received 3,276,000 shares of the
Company’s Common Stock upon conversion. Mr. Salvo received 3,354,645 shares of the Company’s Common Stock
upon conversion.
Non-controlling
Interest
Mr.
Berkman agreed, under certain conditions to transfer the remaining 49% of the HDS equity to the Company for a consideration of
$1.00. On December 1, 2018, the Company and Mr. Berkman entered into an Agreement, Assignment and Release, pursuant to which Mr.
Berkman transferred the remaining HDS equity interests to the Company, waiving and releasing any conditions to such transfer.
As of December 1, 2018, HDS is a wholly owned subsidiary of the Company. During the six months ended in January 31, 2019, there
was a net loss attributable to the non-controlling interest (49%) in HDS of $122,692 and contributions made of $133,679. As of
January 31, 2019, and July 31, 2018, the non-controlling interest in HDS was $0 and $5,576,272, respectively.
Pursuant
to the Company’s acquisition of Regentys on January 7, 2019 to acquire a 51% interest, the Company was issued 12,048,161
shares of Regentys common stock. As of January 31, 2019, Regentys had a total of 18,623,278 shares of common stock and 2,793,192
Series A voting preferred stock for a total of 21,416,470 total voting shares outstanding. As such, there are 9,368,309 of shares
that belong to non-controlling interest shareholders which represents a 43.74% non-controlling interest.
Pursuant
to the Company’s acquisition of Olaregen on January 7, 2019 to acquire a 51% interest, the Company was issued 3,282,632
shares of Olaregen common stock. As of January 31, 2019, Olaregen had a total of 5,648,819 shares of common stock and 592,683
Series A voting preferred stock for a total of 6,241,502 total voting shares outstanding. As such, there are 2,958,870 of shares
that belong to non-controlling interest shareholders which represents a 47.41% non-controlling interest.
On
November 1, 2018, the Company completed its second closing of Veneto Holdings, L.L.C. (“Veneto”) which granted the
Company of Rapport Services, LLC (“Rapport”) through the ownership of the units of Class B membership interests providing
control of Rapport as only the Class B Member is entitled to elect the nominees to the Board of Managers, which constitute a one
percent (1%) ownership in Rapport. The remaining interests represent a 99% non-controlling interest.
Note
8 – Redeemable Non-Controlling Interest:
Pursuant
to the Company’s acquisition of 51% of the outstanding capital stock of Regentys, Regentys had authorized 7,500,000 shares
of redeemable Series A Convertible Preferred Stock (“Preferred Stock A”), with a par value of $0.0001 and redemption
value of $0.65 per share of which 2,793,192 Preferred Stock A was outstanding as of the date of acquisition and as of January
31, 2019. Preferred Stock may be converted into common stock at the initial conversion ratio of 1:1 which ratio shall be adjusted
in accordance with stock dividends, splits, combinations and other similar events, including the sale of additional shares of
common or preferred stock and the holders of Preferred Stock A are entitled to vote, together with the holders of Regentys common
stock, on all matters submitted to stockholders of Regentys for a vote. At any time after November 1, 2026, the holders of
the Company’s Series A Preferred Stock will have the right to require the Company to redeem all or a portion of their shares
for cash at a redemption price equal to its liquidation value. Accordingly, this Preferred Stock A was valued to be $4,073,898
at the time of acquisition of Regentys and reclassified as Redeemable Non-Controlling Interest outside of stockholders’
deficit on the condensed interim consolidated balance sheets.
Note
9- Stock-Based Compensation
:
Stock
Option Plans
As
of January 31, 2019, the Company had two stockholder-approved stock incentive plans under which shares and options exercisable
for shares of common stock have been or may be granted to employees, directors, consultants and advisors. A total of 2,835,000
shares of common stock are reserved for issuance under the 2006 Stock Plan as amended (the 2006 Plan) and 240,000,000 shares of
common stock reserved for issuance under the 2017 Stock Option Plan (the 2017 Plan). At January 31, 2019, there were 2,817,150
and 233,779,375 shares of common stock reserved for future awards under the 2006 Plan and 2017 Plan, respectively. The Company
issues new shares of common stock from the shares reserved under the respective Plans upon conversion or exercise of options and
issuance of restricted shares.
The
2006 and 2017 Plans (the Plans) are administered by the Board of Directors (the Board). The Board is authorized to select from
among eligible employees, directors, advisors and consultants those individuals to whom options are to be granted and to determine
the number of shares to be subject to, and the terms and conditions of the options. The Board is also authorized to prescribe,
amend and rescind terms relating to options granted under the Plans. Generally, the interpretation and construction of any provision
of the Plans or any options granted hereunder is within the discretion of the Board.
The
Plans provide that options may or may not be Incentive Stock Options (ISOs) within the meaning of Section 422 of the Internal
Revenue Code. Only employees of the Company are eligible to receive ISOs, while employees and non-employee directors, advisors
and consultants are eligible to receive options which are not ISOs, i.e. “Non-Qualified Options.” The options granted
by the Board in connection with its adoption of the Plans were Non-Qualified Options. In addition, the 2006 Plan also provides
for restricted stock grants.
The
fair value of each option granted is estimated on the grant date using the Black-Scholes option pricing model or the value of
the services provided, whichever is more readily determinable. The Black-Scholes option pricing model takes into account, as of
the grant date, the exercise price and expected life of the option, the current price of the underlying stock and its expected
volatility, expected dividends on the stock and the risk-free interest rate for the term of the option.
The
following is a summary of the common stock options granted, forfeited or expired and exercised under the Plan:
|
|
Options
|
|
Weighted
Average Exercise Price per Share
|
Outstanding - July 31, 2018
|
|
|
232,218
|
|
|
$
|
1.46
|
|
Granted
|
|
|
6,220,625
|
|
|
|
0.47
|
|
Forfeited or expired
|
|
|
(214,371
|
)
|
|
|
(0.05
|
)
|
Exercised
|
|
|
—
|
|
|
|
—
|
|
Outstanding - January 31, 2019
|
|
|
6,238,472
|
|
|
$
|
0.56
|
|
The
6,238,472 outstanding options at January 31, 2019 had a weighted average remaining contractual term of 9.68 years.
There
were 1,891,979 vested common stock options under the Plan for the period ended January 31, 2019. The compensation expense was
$924,845 for the six months ended January 31, 2019. The Company had $222,216 of unrecognized compensation costs related to non-vested
share-based compensation arrangements granted under the Plan at January 31, 2019.
The
Company granted 6,220,625 options during the six months ended January 31, 2019 and none during the year ended July 31, 2018.
The
Company estimated the fair value of each stock option on the grant date using a Black-Scholes option-pricing model. Black-Scholes
option-pricing models requires the Company to make predictive assumptions regarding future stock price volatility, recipient exercise
behavior, and dividend yield. The Company estimated the future stock price volatility using the historical volatility over the
expected term of the option. The following assumptions were used in the Black-Scholes option-pricing model:
|
|
|
January
31,
2019
|
|
Exercise price
|
|
|
$0.64
- 1.08
|
|
Time to expiration
|
|
|
10
years
|
|
Risk-free interest
rate
|
|
|
2.56%
- 3.14%
|
|
Estimated volatility
|
|
|
135.2%
- 143.1%
|
|
Dividend
|
|
|
—
|
|
Stock price at valuation
date
|
|
|
$0.64
- 1.08
|
|
The
following table summarizes information on stock options outstanding at January 31, 2019:
|
|
|
|
|
Options
Outstanding and Options Exercisable
|
|
Range
of Exercise Price
|
|
|
|
Number
Outstanding at January 31, 2019
|
|
|
|
Weighted
Average Exercise Price
|
|
|
|
Weighted
Average Remaining Life (Years)
|
|
|
|
Aggregate
Intrinsic Value
|
|
$
|
0.11
|
|
|
|
2,730,000
|
|
|
$
|
0.05
|
|
|
|
9.68
|
|
|
$
|
5,525,000
|
|
|
0.64
|
|
|
|
1,328,125
|
|
|
|
0.14
|
|
|
|
9.76
|
|
|
|
1,978,906
|
|
|
0.78
|
|
|
|
1,712,500
|
|
|
|
0.21
|
|
|
|
9.87
|
|
|
|
2,311,875
|
|
|
0.92
|
|
|
|
200,000
|
|
|
|
0.03
|
|
|
|
9.92
|
|
|
|
242,000
|
|
|
1.08
|
|
|
|
250,000
|
|
|
|
0.04
|
|
|
|
9.93
|
|
|
|
262,500
|
|
|
30.48
|
|
|
|
17,850
|
|
|
|
0.09
|
|
|
|
1.10
|
|
|
|
—
|
|
|
|
|
|
|
6,238,475
|
|
|
$
|
0.56
|
|
|
|
9.74
|
|
|
$
|
10,320,281
|
|
The
intrinsic value is calculated as the difference between the market value and the exercise price of the shares on January 31, 2019.
The market values as of January 31, 2019 was $2.13 based on the closing bid price for January 31, 2019
Note
10 – Acquisitions:
Hema
Diagnostics Systems, LLC:
On
January 18, 2017, the Company acquired a 51% interest in Hema Diagnostic Systems, LLC (“HDS”), pursuant to the Acquisition
Agreement. At closing, the Company acquired 4,950 of HDS’s 10,000 previously outstanding limited liability company units
in exchange for 1,117,011 shares of Generex common stock valued at $253,721, plus 420 shares of Generex common stock issued to
HDS in exchange for 300 new limited liability company units. The Acquisition Agreement also provides the Company with a call option
to acquire the remaining 49% of HDS and a retirement of HDS shareholder loans in the amount of $13,431,706 (including interest)
(the “Call Option”) for the aggregate purchase price of $1. On November 30, 2018, the call option was exercised, and
the Company acquired the remaining 49% of HDS.
Following
the closing and the completion of Company’s reverse stock split, the Company was required to issue a further 4,830,000 shares
of common stock and issue a warrant to a former shareholder of HDS to acquire 15,000,000 additional shares of Generex common stock
for $2.50 per share. The issue of this warrant is contingent upon the Company obtaining approval from its shareholders for an
increase in its authorized share capital. The total consideration was valued at $1,350,916 on the date of the acquisition. As
of January 31, 2019, all warrants relating to this acquisition have been issued which resulted in additional paid in capital of
$9,032,435.
Fair
Value of the HDS Assets
The
intangibles assets acquired include In–Process Research & Development (“IPR&D”). The Fair Value of the
IPR&D intangible asset using an Asset Cost Accumulation methodology as of January 18, 2017 (the “Valuation Date”)
was determined to be $2,911,377.
The
net purchase price of HDS was determined to be as follows:
|
|
Stock
Price at Closing
|
|
Shares
|
|
Fair
Value
|
Purchase price:
|
|
|
|
|
|
|
|
|
|
|
|
|
Common
Stock at closing
|
|
$
|
.23
|
|
|
|
1,117,011
|
|
|
$
|
253,721
|
|
Common
Stock after closing
|
|
$
|
.23
|
|
|
|
420
|
|
|
|
95
|
|
Common
Stock post reverse stock split
|
|
$
|
.23
|
|
|
|
4,830,000
|
|
|
|
1,097,100
|
|
Total
purchase price
|
|
|
|
|
|
|
5,947,431
|
|
|
$
|
1,350,916
|
|
As
of January 18, 2017, the issue of the warrant to acquire 15,000,000 additional common shares of Generex was contingent upon shareholder
approval of an increase in the Company’s authorized capital stock. No warrant could be issued by the Company until such
time that an increase in authorized capital has been approved. At the time of closing, Management was not of the opinion that
it is more likely than not that the warrant will be issued and the Call Option will be exercised, accordingly no values have been
attributed to the warrant and Call Option at closing. During 2017, management made a redetermination and estimated that it was
more likely than not that the shareholder approval to increase authorized share capital would be obtained and the Call Option
would be exercised.
On
December 1, 2018, pursuant to the Acquisition Agreement the Company issued the warrant to 15,000,000 additional common shares
of Generex to Stephen L. Berkman. The Warrant is exercisable until December 1, 2019 at an exercise price of $2.50 per share. The
Warrant contains a provision prohibiting the exercise of the Warrant to the extent that, after exercise, Mr. Berkman would own
more than 9.99% of the Company’s common stock. The Warrant was issued pursuant to the January 18, 2017 Acquisition Agreement
among the Company, Hema Diagnostic Systems, LLC (“HDS”), Stephen L. Berkman and the other equity owners of HDS. Despite
the warrants being issued after the effective date of the 20 for 1 stock dividend, per an agreement with warrant holder, such
warrants were not subject to the stock dividend and no adjustment was made to the exercise price.
Simultaneously,
on December 1, 2018, Company exercised the Call Option and acquired the remaining 49% non-controlling interest in HDS. Accordingly,
the fair values of the warrants and call option was updated through the issuance and exercise date and the change in the fair
value of the contingent purchase consideration of $(4,397,507) and $15,147591 was recorded and included in the condensed interim
consolidated statements of operations and comprehensive income for the three- and six-months ending January 31, 2019.
The
Company adopted a sequencing policy and determined that the warrants with fixed exercise price were excluded from derivative consideration.
The
remaining fair value of the call option and the warrant payable remaining at the time of exercise of the call option and issuance
of the warrant was charged against additional paid-in capital as an elimination of non-controlling interest for $(6,951,015).
Fair
Value Assumptions Used in Accounting for the Warrant
The
Company used the Black-Scholes option-pricing model to calculate the fair value of the warrant as of January 31, 2019. The Black-Scholes
option-pricing model requires six basic data inputs: the exercise or strike price, time to expiration, the risk-free interest
rate, the current stock price, the estimated volatility of the stock price in the future, and the dividend rate. The key inputs
used in the fair value calculations were as follows:
|
|
December
1,
2018
|
|
July
31,
2018
|
Exercise price
|
|
|
2.50
|
|
|
|
2.50
|
|
Time to expiration
|
|
|
3.14
years
|
|
|
|
3.47
years
|
|
Risk-free interest
rate
|
|
|
3.01
|
%
|
|
|
2.77
|
%
|
Estimated volatility
|
|
|
138.61
|
%
|
|
|
143.97
|
%
|
Dividend
|
|
|
—
|
|
|
|
—
|
|
Stock price at valuation
date
|
|
$
|
0.9
|
|
|
$
|
0.1
|
|
Fair
Value Assumptions Used in Accounting for Call Option
The
Company used the Monte Carlo model to calculate the fair value of the call option as of six months ended January 31, 2019 and
year ended July 31, 2018. The valuations are based on assumptions as of the valuation date with regard to the value of the asset
acquired net of impairment, the risk-free interest rate, the estimated volatility of the stock price in the future, the time to
expiration and the stock price at the date of valuation.
The
following assumptions were used in estimating the value of the Call Option:
|
|
December
1,
2018
|
|
July
31,
2018
|
Risk-free
interest rate
|
|
|
2.52
|
%
|
|
|
2.44
|
%
|
Estimated volatility
|
|
|
164.43
|
%
|
|
|
129.95
|
%
|
Remaining Term
|
|
|
1.13
years
|
|
|
|
1.47
years
|
|
Stock price at valuation
date
|
|
$
|
0.9043
|
|
|
$
|
0.0976
|
|
Grainland
and Empire Pharmacies:
On
December 28, 2017, the Company through its wholly owned subsidiary NuGenerex, completed the acquisition of the assets and 100%
of the membership interests of two pre-operational pharmacies, Empire State Pharmacy Holdings, LLC and Grainland Pharmacy Holdings,
LLC, pursuant to the bills of sale for a consideration of $320,000 Promissory Note due and payable in full on June 28, 2018 bearing
an annual interest rate of 3%. The note was extended by six months and set to mature with the same terms on December 28, 2018.
The note remains active and interest has continued to accrue while new terms of the note are in process of being negotiated.
We
finalized our allocation of the purchase price as of January 31, 2019. The final allocation of the purchase price as of January
31, 2019, is as follows:
|
|
Preliminary
Allocation as of December 28,
2017
|
|
Allocation
Adjustments
|
|
Final
Allocation
|
Intangible
assets (licenses)
|
|
$
|
276,380
|
|
|
$
|
—
|
|
|
$
|
276,380
|
|
Property
and equipment
|
|
|
19,879
|
|
|
|
—
|
|
|
|
19,879
|
|
Computer
software acquired
|
|
|
5,980
|
|
|
|
—
|
|
|
|
5,980
|
|
Leasehold
Improvements
|
|
|
17,761
|
|
|
|
—
|
|
|
|
17,761
|
|
Total
assets acquired
|
|
|
320,000
|
|
|
|
—
|
|
|
|
320,000
|
|
Consideration:
|
|
|
|
|
|
|
|
|
|
|
|
|
Note
Payable
|
|
|
320,000
|
|
|
|
|
|
|
|
320,000
|
|
Goodwill
|
|
$
|
—
|
|
|
|
|
|
|
$
|
—
|
|
The
entire value of the intangible assets represent the licenses obtained to operate a pharmacy in the respective state of each of
the acquired pharmacies. Intangible assets are generally amortized on a straight-line basis over the useful lives of the assets.
The Company is currently not amortizing the pharmacy license until the pharmacies becomes commercially viable and operations begin
in the acquired pharmacies. At the time, when the licenses are placed in service, the Company will determine a useful life.
Since
acquisition, Grainland Pharmacy Holdings, LLC ceased to operate. Accordingly, the value allocated to its tangible assets, leasehold
improvements and licenses acquired for $99,519 was charged to impairment of long-live assets.
Veneto:
On
October 3, 2018, the Company entered into an Asset Purchase Agreement (the “Agreement”) with Veneto Holdings, L.L.C.
(“Veneto”) to purchase certain assets of Veneto.
Effective
as at October 3, 2018, NuGenerex Distribution Solutions, LLC assigned the Veneto Asset Purchase Agreement to NuGenerex Distribution
Solutions 2, LLC. The sole member of that LLC is NuGenerex Management Services, Inc., a wholly-owned subsidiary of Generex
Biotechnology Corporation.
The
aggregate purchase price for the Assets, is $35,000,000 including the Promissory Note. At the Second Closing, the Company
will pay the principal of the Promissory Note plus interest to Veneto, (i) $9,000,000 will be paid by the Company into a trust
or other fiduciary account acceptable to Veneto to be used exclusively for satisfaction of certain contingent liabilities of Veneto
and subsidiaries of Veneto not being acquired by the Company, (ii) $3,000,000 will be paid by the Company into an escrow account
to secure potential obligations of Veneto in respect of the Second Closing date working capital and under the indemnification
provisions of the Agreement and (iii) the balance will be payable directly to Veneto in cash.
The
Company had also entered into a temporary fee-for-service arrangement with Veneto and one of its subsidiaries for Veneto to provide
management, personnel, operational, administrative and other services with respect to the First Closing Assets pending the Second
Closing. At the Second Closing, all of Veneto personnel providing these services became employees or consultants of the Company,
and, therefore, Veneto no longer provides these services.
At
the First Closing, the Promissory Note issued to Veneto in the original principal amount of $15,000,000 with interest at an annual
rate of 5.0% and guaranteed by Generex and Joseph Moscato, and secured by a first priority security interest in the Company’s
assets other than the First Closing Assets was subsequently cancelled upon the issuance of the new promissory note on the Second
Closing in the principal amount of $35,000,000 with an annual of 12.0% and guaranteed by Generex and Joseph Moscato. There was
$62,500 of accrued interest on the $15,000,000 note and an additional $1,050,000 of accrued interest on the new $35,000,000 promissory
note for a total of $1,112,500 of accrued interest for the six months ended January 31, 2019.
On
November 1, 2018 the Company consummated the acquisition of the Second Closing Assets, consisting primarily of Veneto’s
management services organization business and two additional ancillary services. The aggregate price for the First Closing Assets
and the Second Closing Assets was $30,000,000. The Company issued a promissory note in the principal amount of $35,000,000 (the
“
New Note
”) consisting of the $30,000,000 purchase price and a $5,000,000 original issue discount, as the sole
consideration payable on the Second Closing Date. In addition, we agreed to assume approximately $3.8 million in outstanding institutional
debt of Veneto subsidiaries, but will have the use of Veneto cash which would otherwise have been applied to paying down the debt.
On
March 29, 2019, the Company entered into an Amendment Agreement (the “
Amendment
”) with Veneto and the equity
owners of Veneto (the “Veneto Members”) entered into restructuring the payment of the New Note that provided in lieu
of any cash payments, the Company would deliver 8,400,000 shares of the Company’s common stock (the “Generex Shares”)
to be delivered on or before April 22, 2019; plus an aggregate 5,500,000 shares of the Company’s subsidiary, common stock
of Antigen Express, Inc. The Company and the Veneto Members established a value of the Company’s common stock related to
this conversion of debt at $2.50/share, but upon a final pay date of June 14, 2020 (the “Pay Date”) the Veneto Members
will receive additional compensatory shares if following results in a positive number: $2.50 (the “Strike Price") per
Generex Shares times the shares issued (8,400,000) minus the Sale Price of the proceeds of sale of any Generex Shares by the Members
in the interim (“Sale Price”) times the number of Generex Shares sold (“Shares Sold”) divided by the Spot
Price of the price of the common voting shares of the Company’s common stock on the Pay Date (“Spot Price”).
Any sale above the Strike Price shall be discarded. The Sale Price shall, for calculation under this agreement shall be no less
than $1.50 per share. Any actual proceeds of sale that are less than $1.50 per shares shall be calculated at $1.50 regardless
of the actual proceeds of sale. As such, the Veneto Members shall have downside protection from $2.50 to $1.50. The downside protection
lapses if the volume weighted average price of the Generex Shares, in any period of 90 consecutive trading days, is over $5 per
share.
Fair
Value of the Veneto Acquisition
The
following table summarizes the allocation of the preliminary purchase price as of the Veneto acquisition as of the First Closing
and the Second Closing:
|
|
“First
Closing” completed on
October
3, 2018
|
|
“Second
Closing” completed on
November
1, 2018
|
|
Total
|
Cash
and cash equivalents
|
|
$
|
2,410,150
|
|
|
$
|
—
|
|
|
$
|
2,410,150
|
|
Accounts
receivable, net
|
|
|
1,935,078
|
|
|
|
—
|
|
|
|
1,935,078
|
|
Inventory,
net
|
|
|
1,068,856
|
|
|
|
—
|
|
|
|
1,068,856
|
|
Prepaid
expenses
|
|
|
95,804
|
|
|
|
—
|
|
|
|
95,804
|
|
Property
and equipment, net
|
|
|
652,590
|
|
|
|
—
|
|
|
|
652,590
|
|
Other
receivables
|
|
|
1,014,316
|
|
|
|
—
|
|
|
|
1,014,316
|
|
Notes
receivable - LT
|
|
|
1,387,763
|
|
|
|
—
|
|
|
|
1,387,763
|
|
Other
assets, net
|
|
|
25,745
|
|
|
|
—
|
|
|
|
25,745
|
|
Intangible
assets, net
|
|
|
35,603
|
|
|
|
7,110,000
|
|
|
|
7,145,603
|
|
Total
assets acquired
|
|
|
8,625,905
|
|
|
|
7,110,000
|
|
|
|
15,735,905
|
|
Total
current liabilities
|
|
|
2,509,887
|
|
|
|
—
|
|
|
|
2,509,887
|
|
Notes
payable
|
|
|
—
|
|
|
|
3,403,948
|
|
|
|
3,403,948
|
|
Total
liabilities assumed
|
|
|
2,509,887
|
|
|
|
3,403,948
|
|
|
|
5,913,835
|
|
Net
identifiable assets acquired
|
|
|
6,116,018
|
|
|
|
3,706,052
|
|
|
|
9,822,070
|
|
Goodwill
|
|
|
8,883,982
|
|
|
|
16,293,948
|
|
|
|
25,177,930
|
|
Total
consideration transferred
|
|
$
|
15,000,000
|
|
|
$
|
20,000,000
|
|
|
$
|
35,000,000
|
|
The
note receivable for $1,387,763 acquired during the first closing of Veneto on October 3, 2018 has since accrued additional interest
and holds a balance of $1,406,051 as of January 31, 2019.
The
significant intangible assets identified in the purchase price allocation discussed above include developed software and technology,
referral base (recurring revenue from the MSO investments and their use of Company owned pharmacies) and non-compete agreements
with continued employment of key employees. Tradenames and trademarks were not valued as tradenames and trademarks will not be
maintained going forward. To value the developed software and technology, the Company utilized the relief from royalty method,
a form of the income approach to value the developed software and technology which assumes a limited technology life and market
share adjusted by assumed obsolescence with a terminal value. The referral base was valued using a multi-period excess earnings
method, a form of the income approach. The Company utilized the with and without method, a form of the income approach to value
non-compete agreements with Generex.
The
preliminary amounts assigned to the identifiable intangible assets, the estimated useful lives, and the estimated amortization
expense related to these identifiable intangible assets are as follows:
|
|
Preliminary
Fair
Value
|
|
Average
Estimated
Life
|
Developed
Software/Technology
|
|
$
|
780,000
|
|
|
|
5
|
|
Referral Base
|
|
|
3,920,000
|
|
|
|
15
|
|
Non-compete
agreements
|
|
|
2,410,000
|
|
|
|
3
|
|
|
|
$
|
7,110,000
|
|
|
|
|
|
Intangible
assets are generally amortized on a straight-line basis over the useful lives of the assets.
Goodwill
represents the excess of the purchase price over the fair market value of net assets acquired. Goodwill for Veneto Acquisition
was $8.9 million as of the date of the First Closing and $16.3 million as of the date of the Second Closing.
Regentys
and Olaregen:
On
January 7, 2019, the Company closed two separate Acquisition Agreements pursuant to which the Company acquired a 51% interest
in both Regentys Corporation (“Regentys”) and Olaregen Therapeutix Inc. (“Olaregen”).
The
Company accounted for the acquisitions of both Regentys and Olaregen as business combinations using the purchase method of accounting
as prescribed in Accounting Standards Codification 805, Business Combinations (“ASC 805”) and ASC 820 – Fair
Value Measurements and Disclosures (“ASC 820”). In accordance with ASC 805 and ASC 820, the Company used its best
estimates and assumptions to accurately assign fair value to the tangible assets acquired, identifiable intangible assets and
liabilities assumed as of the acquisition dates. Goodwill as of the acquisition date is measured as the excess of purchase consideration
over the fair value of tangible and identifiable intangible assets acquired and liabilities assumed.
The
fair values assigned to Regentys’ and Olaregen’s tangible and identifiable intangible assets acquired, and liabilities
assumed are based on management’s estimates and assumptions. The estimated fair values of these assets acquired, and liabilities
assumed are considered preliminary and are based on the information that was available as of the date of the acquisition. The
preliminary estimated fair values of assets acquired, and liabilities assumed, and identifiable intangible assets may be subject
to change as additional information is received. Thus, the provisional measurements of fair value are subject to change. The Company
expects to finalize the valuations as soon as practicable, but not later than one year from the closing date.
Regentys:
On
November 28, 2018, Generex and Regentys closed the acquisition of 51% of the outstanding capital stock of Regentys for a total
consideration of fifteen million dollars ($15,000,000). On January 7, 2019 the Company completed a definitive Stock Purchase Agreement
and related documents effecting the transactions contemplated by the LOI.
Pursuant
to a Stock Purchase Agreement between the Company and Regentys (the “Purchase Agreement”) the Company acquired 12,048,161
newly issued shares of the Regentys common stock representing 51% percent of the issued and outstanding capital stock of Regentys
(“Regentys Shares”).
In
addition to $400,000 paid to Regentys upon signing of the LOI, the purchase price for the Regentys Shares will consist of the
following cash payments, with the proceeds intended to be used for specific purposes, as noted:
•
|
|
$3,450,000
to initiate pre-clinical activities on or before January 15, 2018. As of the date this quarterly report was filed, the Company
has paid $650,000 and the remaining balance of $2,800,000 is payable on or before April 1, 2019.
|
•
|
|
$2,000,000
to initiate patient recruitment activities on or before May 1, 2019.
|
•
|
|
$3,000,000
to initiate a first-in-human pilot study on or before September 1, 2019.
|
•
|
|
$5,000,000
to initiate a human pivotal study on or before February 1, 2020.
|
•
|
|
$1,150,000
to submit a 510(k) de novo submission to the FDA on or about February 1, 2021.
|
The
Company issued its Promissory Note in the amount of $14,600,000 (the “Note’) representing its obligation to pay the
above amounts. The Note is secured by a pledge of the Regentys shares pursuant to a Pledge and Security Agreement. In the event
that Generex does not make any of the first three payments listed above, at Regentys’ option either:
•
|
|
Generex
will forfeit all of the Regentys shares issued with no refund of amounts paid; or
|
•
|
|
Generex will issue
shares of its common stock to Regentys equivalent to 110% of the value of the missing payment, which shares will be registered
for resale.
|
In
the event Generex does not make either or both of the fourth and fifth payments, its share ownership of Regentys will be proportionately
reduced.
On
March 14, 2019, the Company and Regentys amended the Stock Purchase Agreement and Promissory Note to extend the due date of the
remaining balance of the first tranche of Guaranteed Payments amounting to $2,800,000 on or before April 1, 2019. The extension
of this due date has no impact on the existing schedule of future payments or any additional terms within the Note. Generex did
not furnish payments on April 1, 2019. Regentys has not filed any notice of default as of the date of publication, and Generex
continues to provide Regentys with business opportunities continuing the relationship.
Fair
Value of the Regentys Acquisition
The
following table summarizes the allocation of the preliminary purchase price as of the Regentys acquisition:
|
|
Preliminary
Allocation
as of
January
7,
2019
|
Cash
and cash equivalents
|
|
$
|
61,857
|
|
Other
current assets
|
|
|
13,138
|
|
Property
and equipment, net
|
|
|
444
|
|
Accounts
payable and accrued liabilities
|
|
|
(1,181,920
|
)
|
Notes
payable
|
|
|
(639,009
|
)
|
Loans
from related parties
|
|
|
(16,506
|
)
|
Net
Tangible Assets
|
|
$
|
(1,761,996
|
)
|
Note
receivable from Generex
|
|
|
14,345,205
|
|
In-process
research & development
|
|
|
3,510,680
|
|
Deferred
tax liability
|
|
|
(889,782
|
)
|
Redeemable
non-controlling interest
|
|
|
(4,073,898
|
)
|
Non-controlling
interest
|
|
|
(9,870,762
|
)
|
Total
Fair Value of Assets Acquired
|
|
|
1,259,447
|
|
Consideration:
|
|
|
|
|
Cash
paid prior to the time of closing
|
|
|
400,000
|
|
Note
receivable from Generex
|
|
|
14,345,205
|
|
Total
Purchase Price
|
|
|
14,745,205
|
|
Goodwill
|
|
$
|
13,485,758
|
|
The
redeemable non-controlling interest of $4,073,898, representing the Series Stock A, was determined by deducting the total consideration
paid of $14,745,205 from the total purchase value totaling $28,689,865 based on a convergence method in an Option Pricing Model
using the Regentys capital structure with 12,048,161 newly issued shares of the Regentys common stock representing 51% percent
of the issued and outstanding capital stock of Regentys. See Note 8 –
Redeemable Non-Controlling Interest.
Olaregen:
On
November 27, 2018, Generex and Olaregen entered into a binding letter of intent (“LOI”) contemplating the Company’s
acquisition of 51% of the outstanding capital stock of Olaregen for a total consideration of twelve million dollars ($12,000,000).
As of January 7, 2019, the Company completed a definitive Stock Purchase Agreement (“Purchase Agreement”) and related
documents effecting the transactions contemplated by the LOI.
The
Company acquired 3,282,632 newly issued shares of the Olaregen common stock representing 51% percent of the issued and outstanding
capital stock of Olaregen (“Olaregen Shares”).
In
addition to $400,000 paid to Olaregen upon signing of the LOI, the purchase price for the Olaregen Shares will consist of the
following cash payments:
•
|
|
$800,000
on or before January 15, 2019. The Company has paid this installment.
|
•
|
|
$800,000
on or before January 31, 2019. As of the date this quarterly report was filed, the Company has paid $200,000 of this installment
and remaining balance of $600,000 is payable on or before April 1, 2019.
|
•
|
|
$3,000,000
on or before April 1, 2019.
|
•
|
|
$1,000,000.
On or before May 31, 2019.
|
•
|
|
$6,000,000.00
on or before September 30, 2019.
|
The
Company issued its Promissory Note in the amount of $11,600,000 (the “Note’) representing its obligation to pay the
above amounts. The Note is secured by a pledge of the Olaregen shares pursuant to a Pledge and Security Agreement. In the event
that Generex fails to pay the installment due on September 30, 2019, Generex will forfeit the shares allocated to that installment
(1,600,000 Olaregen shares) and Olaregen will be entitled to “claw back” fifty percent (50%) of any and all shares
paid for by the prior payments.
On
March 14, 2019, the Company and Olaregen amended the Stock Purchase Agreement and Promissory Note to extend the due date of the
remaining balance of the second tranche of Guaranteed Payments amounting to $600,000 on or before April 1, 2019. The extension
of this due date has no impact on the existing schedule of future payments or any additional terms within the Note. Generex did
not furnish payments on April 1, 2019. Olaregen has not filed any notice of default as of the date of publication, and Generex
continues to provide Olaregen with business opportunities continuing the relationship.
In
the event Generex does not make any other payments, its share ownership of Olaregen will be proportionately reduced.
Generex
has a limited anti-dilution right under the Purchase Agreement, to ensure that Generex will retain 51% ownership in Olaregen for
a period of time.
Fair
Value of the Olaregen Acquisition
The
following table summarizes the allocation of the preliminary purchase price as of the Olaregen acquisition:
|
|
Preliminary
Allocation
as of
January
7, 2019
|
Cash
and cash equivalents
|
|
$
|
608,419
|
|
Prepaid expenses
|
|
|
20,488
|
|
Inventory
|
|
|
408,501
|
|
Other current assets
|
|
|
37,950
|
|
Accounts payable
|
|
|
(216,670
|
)
|
Accrued
liabilities
|
|
|
(216,694
|
)
|
Net
Tangible Assets
|
|
$
|
641,994
|
|
Note receivable
from Generex
|
|
|
11,472,663
|
|
In-process research
& development
|
|
|
3,980,000
|
|
Non-compete agreement
|
|
|
790,000
|
|
Deferred tax liability
|
|
|
(1,040,173
|
)
|
Non-controlling
interest
|
|
|
(11,999,559
|
)
|
Total
assets acquired
|
|
$
|
3,844,925
|
|
Non-controlling
interest
|
|
|
—
|
|
Consideration:
|
|
|
|
|
Cash paid prior
to the time of closing
|
|
|
400,000
|
|
Note
receivable from Generex
|
|
|
11,472,663
|
|
Goodwill
|
|
$
|
8,027,738
|
|
The
components of the acquired intangible assets were as follows:
|
|
Preliminary
Fair Value
|
|
Average
Estimated Life
|
In-process
research and development
|
|
$
|
3,980,000
|
|
|
|
—
|
|
Non-compete
agreement
|
|
|
790,000
|
|
|
|
3
|
|
|
|
$
|
4,770,000
|
|
|
|
|
|
Deferred
Tax Liability
As
a result of the acquisition of Regentys and Olaregen, the purchase price allocation attributed to deferred tax liability of $889,782
and $1,040,173, respectfully. The Company has deferred tax assets of over $92 million with a full allowance equally to the to
the amount of the deferred tax asset. Although the Company deferred tax assets are in excess of deferred tax liabilities totaling
$1,929,955, the Company cannot offset the deferred tax liabilities against its deferred tax assets due to the uncertainty of the
Company to realize any value of its deferred tax assets. In addition, the Company acquired 51% of each of Regentys and Olaregen,
less than the 80% required to permit the Company to consolidate with Regentys and Olaregen for tax purposes. Therefore, the deferred
tax liabilities will be reported separately until such time that the Company determines otherwise.
Unaudited
Supplemental Pro Forma Data
Unaudited
pro forma results of operations for the six months ended January 31, 2018 and 2017 as though the Company acquired HDS, Veneto,
Olaregen, Grainland, Empire and Regentys (the “Acquired Companies”) on the first day of each fiscal year are set forth
below.
|
|
Six
months Ended
January
31
|
|
|
2018
|
|
2017
|
Revenues
|
|
$
|
5,839,903
|
|
|
$
|
19,407,319
|
|
Cost
of revenues
|
|
|
2,810,874
|
|
|
|
7,622,676
|
|
Gross profit
|
|
|
3,029,029
|
|
|
|
11,784,643
|
|
Operating
expenses
|
|
|
6,406,594
|
|
|
|
13,592,954
|
|
Operating loss
|
|
|
(3,377,565
|
)
|
|
|
(1,808,311
|
)
|
Other
income (expense)
|
|
|
(202,760
|
)
|
|
|
(123,688
|
)
|
Net
loss
|
|
$
|
(3,580,325
|
)
|
|
|
(1,931,999
|
)
|
Comprehensive net
loss
|
|
$
|
(3,580,325
|
)
|
|
$
|
(1,931,999
|
)
|
Note
11 – Goodwill and Intangible Assets
Goodwill
and Intangible Assets
The
change in the carrying amount of goodwill and other intangible assets for the year ended July 31, 2018 and six-month period ended
January 31, 2019, is as follows:
|
|
Total
|
|
Goodwill
|
|
Other
Intangibles, net
|
Balance
as of July 31, 2018
|
|
$
|
3,187,757
|
|
|
$
|
—
|
|
|
$
|
3,187,757
|
|
Acquisition of Veneto
- "First Closing"
|
|
|
8,919,585
|
|
|
|
8,883,982
|
|
|
|
35,603
|
|
Acquisition of Veneto
- "Second Closing"
|
|
|
23,403,948
|
|
|
|
16,293.948
|
|
|
|
7,110,000
|
|
Purchase of intangible
assets
|
|
|
26,488
|
|
|
|
—
|
|
|
|
26,488
|
|
Acquisition of Regentys
|
|
|
16,996,438
|
|
|
|
13,485,758
|
|
|
|
3,510,680
|
|
Acquisition of Olaregen
|
|
|
12,797,737
|
|
|
|
8,027,737
|
|
|
|
4,770,000
|
|
Close of Grainland
Pharmacy
|
|
|
(88,311
|
)
|
|
|
—
|
|
|
|
(88,311
|
)
|
Amortization of
Veneto developed software/technology
|
|
|
(39,000
|
)
|
|
|
—
|
|
|
|
(39,000
|
)
|
Amortization of
Veneto referral base
|
|
|
(65,333
|
)
|
|
|
—
|
|
|
|
(65,333
|
)
|
Amortization of
Veneto non-compete agreement
|
|
|
(200,833
|
)
|
|
|
—
|
|
|
|
(200,833
|
)
|
Amortization
of Olaregen non-compete agreement
|
|
|
(17,315
|
)
|
|
|
—
|
|
|
|
(17,315
|
)
|
Balance
as of January 31, 2019
|
|
$
|
64,921,161
|
|
|
$
|
46,691,425
|
|
|
$
|
18,229,736
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Intangible
assets are generally amortized on a straight-line basis over the useful lives of the assets. The Company is currently not amortizing
the in-process research and development until it becomes commercially viable and placed in service. At the time when the intangible
assets are placed in service the Company will determine a useful life. As noted in Note 10, the non-compete agreement acquired
in conjunction with the Olaregen acquisition is currently being amortized over a 3 year useful life.
Goodwill
represents the excess of the purchase price over the fair market value of net assets acquired. Goodwill for HDS was $13.4 million
as of the date of the acquisition. When the acquisition transaction closed in January 2017, HDS was a development-stage entity
and its liabilities exceeded the aggregate value of its assets. Utilizing discounted cash flow (DCF) valuation methodology, Generex
determined that HDS has forecasted losses throughout the reasonably foreseeable future with a nominal terminal value. In addition,
there was a high degree of uncertainty as to the future cash flows of HDS. Therefore, the Company concluded that the implied goodwill
arising out of the acquisition was zero and should be properly characterized as fully impaired as of July 31, 2018.
Note
12 – Notes Payable
On
October 26, 2018, Generex entered into a Securities Purchase Agreement with an investor pursuant to which the Company agreed to
sell and sold its Note Due October 26, 2019 (“Note”) in the principal amount of $682,000
.
The purchase
price of the Note was $550,000 from which Generex was required to pay the $15,000 fee of the investor’s counsel. The remaining
$122,000 of principal amount represents original issue discount. The Note does not bear any stated interest in addition to the
original issue discount. The effective interest is 27.5%.
On
November 25, 2018, Generex entered into a Securities Purchase Agreement with an investor pursuant to which the Company agreed
to sell and sold its Note Due November 26, 2019 (“Note”) in the principal amount of $1,060,000. The purchase price
of the Note was $1,000,000. The remaining $60,000 of principal amount represents original issue discount. The Note does not bear
any stated interest in addition to the original issue discount.
On
January 24, 2019, Generex entered into Securities Purchase Agreements with 3 investors pursuant to which the Company agreed to
sell and sold convertible notes bearing interest at 10% per annum (the “Notes”) in the aggregate principal amount
of $2,110,000. The purchase price of the Notes was $2,010,000 and the remaining $100,000 of principal amount represents original
issue discount. Pursuant to the Securities Purchase Agreements, Generex also sold warrants to the investors to purchase up to
an aggregate 120,570 shares of common stock.
The
Company issued debts that consist of the issuance of convertible notes with variable conversion provisions. The conversion terms
of the convertible notes are variable based on certain factors, such as the future price of the Company’s common stock.
The number of shares of common stock to be issued is based on the future price of the Company’s common stock. The number
of shares of common stock issuable upon conversion of the promissory note is indeterminate. Due to the fact that the number of
shares of common stock issuable could exceed the Company’s authorized share limit, the equity environment is tainted and
all additional convertible debentures and warrants are included in the value of the derivative. Pursuant to ASC 815-15 Embedded
Derivatives, the fair values of the variable conversion option and warrants and shares to be issued were recorded as derivative
liabilities on the issuance date.
The
fair values of the Company’s derivative liabilities were estimated at the issuance date and are revalued at each subsequent
reporting date, using a multinomial lattice model. The Company recognized derivative liability on convertible notes of $2,353,139
and derivative liability on warrants of $192,671 at January 31, 2019. The change in fair value of the derivative liabilities resulted
in a gain of $142,725 for the six months ended January 31, 2019.
Subject
to certain ownership limitations, the Notes will be convertible at the option of the holder at any time into shares of the Company’s
common stock at an effective conversion price determined as follows: the lesser of
•
|
|
A
price determined as of the date of closing; and
|
•
|
|
70%
of the lowest volume weighted average trading price of the common stock on the ten days prior to conversion.
|
Pursuant
to the Company’s closing of the acquisition of Veneto, the aggregate purchase price for the Assets is $35,000,000 which
is included as a Promissory Note. Refer to Note 10 for details.
Pursuant
to its wholly owned subsidiary NuGenerex, the Company completed the acquisition of the assets and 100% of the membership interests
of two pre-operational pharmacies, Empire State Pharmacy Holdings, LLC and Grainland Pharmacy Holdings, LLC, pursuant to the bills
of sale for a consideration of $320,000 Promissory Note. Refer to Note 10 for details.
Pursuant
to its acquisition of Regentys, the Company inherited convertible notes with several investors which collectively holds a principal
balance plus accreted interest of $610,369 as of January 31, 2019.
Note
13 - Subsequent Events:
The
Company has evaluated subsequent events occurring after the balance sheet date through the date the unaudited condensed interim
consolidated financial statements were issued.
Generex
Biotechnology Corporation (“Generex”) will issue to holders of Generex common stock a dividend of shares of its wholly
owned subsidiary Antigen Express, Inc., d/b/a NuGenerex Immuno-Oncology. Generex shareholders will receive a dividend of one share
of Antigen Express, Inc. for every four shares of Generex common stock. The Record Date for the dividend was January 30, 2019,
the Payment Date is February 25, 2019.
On
February 8, 2019, Generex Biotechnology Corporation (the “Company”) closed under a Securities Purchase Agreement with
an investor pursuant to which the Company agreed to sell and sold a convertible note bearing interest at 10% per annum (the “Note”)
in the principal amount of $750,000. The purchase price of the Note was $712,500 and the remaining $37,500 of principal amount
represents original issue discount. Pursuant to the Securities Purchase Agreements, the Company also sold to the Investor warrants
to purchase up to an aggregate 45,000 shares of common stock.
On
February 15, 2019, Generex Biotechnology Corporation (the “Company”) entered into, and on February 22, 2019, Generex
closed under a Securities Purchase Agreement with an investor pursuant to which the Company agreed to sell and sold a convertible
note bearing interest at 10% per annum (the “Note”) in the principal amount of $750,000
.
The purchase
price of the Note was $712,500 and the remaining $37,500 of principal amount represents original issue discount. Pursuant to the
Securities Purchase Agreements, the Company also sold to the Investor warrants to purchase up to an aggregate 57,143 shares of
common stock.
On
March 14, 2019, the Company and Olaregen amended the Stock Purchase Agreement and Promissory Note to extend the due date of the
remaining balance of the second payment and the third payment of Guaranteed Payments amounting to $600,000 on or before April
1, 2019.
On
March 14, 2019, the Company and Regentys amended the Stock Purchase Agreement and Promissory Note to extend the due date of the
remaining balance of the first tranche of Guaranteed Payments amounting to $2,800,000 on or before April 1, 2019.
On
March 29, 2019, the Company entered into an Amendment Agreement (the “
Amendment
”) with Veneto and the equity
owners of Veneto (the “Veneto Members”) entered into restructuring the payment of the New Note that provided in lieu
of any cash payments, the Company would delivery 8,400,000 shares of the Company’s common stock (the “Generex Shares”)
to be delivered on or before April 22, 2019; plus an aggregate 5,500,000 shares of the Company’s subsidiary,common stock
of Antigen Express, Inc. The Company and the Veneto Members established a value of the Company’s common stock related to
this conversion of debt at $2.50/share, but upon a final pay date of June 14, 2020 (the “Pay Date”) the Veneto Members
will receive additional compensatory shares if following results in a positive number: $2.50 (the “Strike Price") per
Generex Shares times the shares issued (8,400,000) minus the Sale Price of the proceeds of sale of any Generex Shares by the Members
in the interim (“Sale Price”) times the number of Generex Shares sold (“Shares Sold”) divided by the Spot
Price of the price of the common voting shares of the Company’s common stock on the Pay Date (“Spot Price”).
Any sale above the Strike Price shall be discarded. The Sale Price shall, for calculation under this agreement shall be no less
than $1.50 per share. Any actual proceeds of sale that are less than $1.50 per shares shall be calculated at $1.50 regardless
of the actual proceeds of sale. As such, the Veneto Members shall have downside protection from $2.50 to $1.50. The downside protection
lapses if the volume weighted average price of the Generex Shares, in any period of 90 consecutive trading days, is over $5 per
share.